

# **Investigation of tumour characteristics and treatment strategies in animal models using multiparametric MRI and novel contrast agents**

**Cecilie Brekke Rygh**



Dissertation for the degree philosophiae doctor (PhD)

University of Bergen, Norway

2007

## Acknowledgements

This thesis is based on work carried out at the Department of Biomedicine, University of Bergen, at FUGE Molecular Imaging Center, Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, and at Neuroimaging Group, Institute of Psychiatry, King's College London. I would like to express my sincere gratitude to all those who have contributed to this work in various ways. In particular I would like to thank my colleagues and friends:

Frits Thorsen, my main supervisor during the last two years of my PhD, for invaluable discussions about science and every-day life, his encouragement, support and optimism, and for understanding the trouble of juggling work and parenthood.

Arvid Lundervold, my main supervisor during the first two years of my PhD, for introducing me to the interesting field of MRI and physiology, programming help, his many ideas, and fruitful discussions.

Rolf Bjerkvig, my co-supervisor, for his support when I most needed it, and for his belief in me.

Mike Modo, who supervised me during my stay at IoP, for introducing me to cellular MRI, his patience, and invaluable help with experiments and finishing papers.

Steve Williams, the head of the NeuroImaging group at IoP, for letting me stay and work in his group, his positive attitude, and for providing money necessary to conduct my experiments.

Jack Price for good collaboration and for providing facilities at IoP.

Martha Enger for taking me onboard on her "baby" (the NG2 project) when I was a fresh PhD student, for sharing her enormous amount of knowledge, her friendship and support throughout my PhD.

Sarah Morgan for her friendship, invaluable help and endless patience and great effort in changing me from a "lab disaster" (when it comes to cell culture work) to someone who actually felt that working with cells was joy-bringing.

Christian Brekken, my very knowledgeable co-worker in Trondheim, who is great fun to work with.

My esteemed colleagues at the NeuroImaging group at IoP; Jasdeep Sandhu, Diana Cash, Maria Ashioti, Andrew Lowe, Martina Mitterschiffthaler, Aisling Köning, and the other members of the ratpack for making my stay in London very exciting, fun, and fruitful. Their scientific input and friendship are very much appreciated!

The members of Bjerkvig's lab who immediately made me feel welcome and patiently answered all my stupid questions.

Renate Grüner for reading through my thesis, her superb MR expertise, and encouraging words when needed.

Lars Ermland for his support during hard times and his great sense of humour.

Kenneth Hugdahl, the head of Bergen fMRI group, for financial support to attend HBM 2003 in New York and to buy software.

The personnel at MIC, especially Endy Spriet, for excellent technical assistance.

My good friends and colleagues at BBB; Hilde Gundersen, Eldbjørg Fiske, and Tine Karlsen for discussions about everything but science and for creating such a nice atmosphere at work.

Finally, I would express my gratitude to my family and friends. A warm thank to Kristin and Helge, my dear parents who always have supported me and had strong faith in me, and who have been babysitting Linus every time we have asked for it (and making it sounds like we are doing them a favour). A special thank to Lars Jørgen for being such a fantastic husband and friend. And Linus, my wonderful son, who has taught me the joy of being childish again.

---

## Table of contents

<b>ACKNOWLEDGEMENTS.....</b>	<b>2</b>
<b>LIST OF PAPERS .....</b>	<b>6</b>
<b>ABBREVIATIONS AND GLOSSARY .....</b>	<b>7</b>
<b>INTRODUCTION.....</b>	<b>9</b>
1.1    BASIC PRINCIPLES OF MRI .....	9
1.1.1 <i>Nuclear spin</i> .....	10
1.1.2 <i>Intrinsic contrast mechanisms</i> .....	11
1.2    MR CONTRAST AGENTS IN NEUROIMAGING .....	13
1.2.1 <i>Paramagnetic contrast agents</i> .....	14
1.2.2 <i>Superparamagnetic contrast agents</i> .....	15
1.3    PRIMARY BRAIN TUMOURS .....	16
1.3.1 <i>WHO classification</i> .....	16
1.3.2 <i>The cellular origin of gliomas</i> .....	17
1.3.3 <i>Brain tumour biology</i> .....	18
1.4    CONVENTIONAL AND EXPERIMENTAL TREATMENT STRATEGIES .....	19
1.4.1 <i>Neural stem cells as a potential treatment modality</i> .....	20
1.4.2 <i>NG2 progenitor cells as a potential target for brain tumour therapy</i> .....	21
1.5    EXPERIMENTAL GLIOMA MODELS .....	22
1.6    MR IMAGING OF BRAIN TUMOURS .....	22
1.6.1 <i>Conventional MR imaging</i> .....	23
1.6.2 <i>Functional MR imaging of brain tumours</i> .....	25
1.7    CELLULAR MR IMAGING .....	28
1.7.1 <i>Contrast agents for cellular labelling</i> .....	28

---

1.7.2	<i>Cellular uptake</i> .....	30
1.7.3	<i>Implications of cellular MRI of the CNS using animal models</i> .....	31
1.7.4	<i>Clinical implications of cellular MRI</i> .....	32
<b>2.0</b>	<b>AIMS OF THE THESIS</b> .....	<b>33</b>
<b>3.0</b>	<b>DISCUSSION</b> .....	<b>34</b>
3.1	EXPERIMENTAL DESIGN.....	34
3.1.1	<i>Experimental glioma models</i> .....	34
3.1.2	<i>Quantification of microvascular parameters</i> .....	35
3.1.3	<i>Multiparametric imaging and data analyses</i> .....	37
3.1.4	<i>Contrast agents</i> .....	39
3.2	EXPERIMENTAL FINDINGS .....	40
3.2.1	<i>NG2 expression mediates an aggressive glioma phenotype</i> .....	40
3.2.2	<i>Signal enhancement with differently sized contrast agents</i> .....	41
3.2.3	<i>GRID visualises cells both in vitro, in vivo and ex vivo</i> .....	42
3.2.4	<i>GRID does not impair cellular functions of labelled cells in vitro</i> .....	43
3.2.5	<i>NSCs as a therapeutic modality in brain tumours</i> .....	43
3.3	CONCLUDING REMARKS .....	44
<b>4.0</b>	<b>FUTURE PROSPECTS</b> .....	<b>45</b>
	<b>REFERENCES</b> .....	<b>46</b>

## List of papers

This thesis is based upon the following papers, which are referred to in the text by their Roman numerals.

- I.** Brekke C, Lundervold A, Enger, PØ, Brekken C, Stålsett E, Pedersen TB, Haraldseth O, Krüger PG, Bjerkvig R, and Chekenya M.

**NG2 expression regulates vascular morphology and function in human brain tumours.**

*NeuroImage. 2006 Feb 1;29(3):965-76; Epub ahead of print 2005 Oct 24*

- II.** Brekke C, Morgan SC, Lowe AS, Meade TJ, Price J, Williams SC, and Modo M.

**The in vitro effects of a bimodal contrast agent on cellular functions and relaxometry.**

*NMR in Biomedicine. Epub ahead of print 2006 Sep 1*

- III.** Brekke C, Williams SC, Price J, Thorsen F, and Modo M.

**Cellular multiparametric MRI of neural stem cell therapy in a rat glioma model.**

*Submitted, 2007*

---

## Abbreviations and glossary

<b>ADC</b>	Apparent diffusion coefficient	<b>FDA</b>	US Food and Drug Administration
<b>BBB</b>	Blood-brain-barrier	<b>FLAIR</b>	Fluid attenuated inversion recovery, MRI sequence
<b>BTSC</b>	Brain tumour stem cell	<b>Gd</b>	Gadolinium
<b>C<sub>T</sub></b>	Tissue concentration of a tracer	<b>GE</b>	Gradient echo, MRI sequence
<b>CBV</b>	Cerebral blood volume	<b>GBM</b>	Glioblastoma multiforme
<b>CNR</b>	Contrast-to-noise ratio	<b>GRID</b>	Gadolinium Rhodamine Dextran
<b>CNS</b>	Central nervous system	<b>ICP-MS</b>	Inductively coupled plasma – mass spectrometry
<b>CNS-1</b>	Rat astrocytoma cell line	<b>IR</b>	Inversion recovery, MR sequence
<b>CSC</b>	Cancer stem cell	<b>i.v.</b>	Intravenous
<b>CSF</b>	Cerebral spinal fluid	<b>K<sub>2</sub></b>	Rate constant between EES and blood plasma [min <sup>-1</sup> ] (Su's model)
<b>D<sub>0</sub></b>	Fractional blood volume, i.e. fraction of perfused blood volume [mM] (Su's model)	<b>K<sup>trans</sup></b>	Transfer rate, volume transfer constant between blood plasma and EES, [min <sup>-1</sup> ] (Tofts' model)
<b>D<sub>1</sub></b>	Describes the permeability between the vessels and tissue, is proportional to the transfer constant between vessels and tissue [mM min <sup>-1</sup> ] (Su's model)	<b>k<sub>ep</sub></b>	Rate constant, rate constant between EES and blood plasma [min <sup>-1</sup> ] (Tofts' model)
<b>DCE-MRI</b>	Dynamic contrast enhanced MRI	<b>M</b>	Molar
<b>DSC-MRI</b>	Dynamic susceptibility contrast MRI	<b>M</b>	Bulk magnetisation vector
<b>DWI imaging</b>	Diffusion weighted imaging	<b>M<sub>0</sub></b>	Magnitude of magnetisation vector prior to excitation pulse
<b>EES</b>	Extravascular extracellular space	<b>M<sub>x</sub>, M<sub>y</sub>, M<sub>z</sub></b>	Directional components of M
<b>ECF</b>	Extracellular fluid		

---

<b>MION</b>	Monocrystalline iron-oxide particles	<b>TE</b>	Echo time
<b>MPIO</b>	Micrometer-sized iron-oxide particles	<b>T</b>	Tesla
<b>MRI</b>	Magnetic resonance imaging	<b>T1</b>	Longitudinal relaxation time constant [s]
<b>MVD</b>	Microvessel density	<b>T2</b>	Transverse relaxation time constant [s]
<b>NG2</b>	Neuron-glia 2	<b>TR</b>	Repetition time
<b>NMR</b>	Nuclear magnetic resonance	<b>U251</b>	Human glioblastoma cell line
<b>NSC</b>	Neural stem cell	<b>U251-NG2</b>	U251 cells that are modified genetically to express NG2
<b>PD</b>	Proton density	<b>U251-WT</b>	The wild type counterpart to U251-NG2
<b>Pixel</b>	Picture element	<b>USPIO</b>	Ultrasmall superparamagnetic iron-oxide particles
<b>R</b>	Relaxation rate [ $s^{-1}$ ]	<b>v<sub>e</sub></b>	EES, volume of extravascular extracellular space per unit volume of tissue, i.e. volume fraction of EES or leakage space (Tofts' model).
<b>r</b>	Relaxivity of the contrast agent [ $mM^{-1} s^{-1}$ ]	<b>Voxel</b>	Volume element
<b>RARE</b>	Rapid acquisition with relaxation enhancement, MRI sequence	<b>WHO</b>	World Health Organization
<b>ROI</b>	Region of interest	<b>WT</b>	Wild type
<b>RF</b>	Radiofrequency		
<b>SE</b>	Spin echo, MRI sequence		
<b>SPIO</b>	Superparamagnetic iron-oxide particles		



## **Introduction**

### **Preface**

Magnetic resonance imaging (MRI) has emerged as a powerful and robust tool in the identification and study of diseases in the central nervous system (CNS) since it was first introduced in 1970s. MRI is in many cases the method of choice in diagnosis and treatment evaluation, due to its unique soft tissue contrast, high spatial resolution and physiological sensitivity. Also, as it is non-invasive and utilises non-ionising radiation, MRI is considered as a safe and reliable imaging method (2).

Magnetic resonance is based on the magnetic properties of atomic nuclei, and this phenomenon was first described in 1938 (3). A few years later, Felix Bloch and Edward Purcell independently reported detections of magnetic resonance in bulk matter (4-6). In 1971, the American physician Raymond Damadian stated that nuclear magnetic resonance (NMR) could distinguish between cancerous and healthy tissue, and for the first time a clear biological application of NMR was shown (7). The first MR image was generated in 1972 by Paul Lauterbur, and reported in *Nature* in 1973 (8) after first being rejected by the same journal due to lack of wide significance. Improvements of image formation by Peter Mansfield in 1976 greatly improved the feasibility of MRI. In 1977, the first human magnetic resonance scanner was developed by Damadian's FONAR Corporation (2). The US Food and Drug Administration (FDA) approved MRI scanners for clinical use in 1985 (2). The first MRI scanner in Norway was installed at Stavanger University Hospital in 1986. Over the years, the number of MRI scanners has exploded, and are extensively used both in clinical and research settings. In 2003, Peter Mansfield and Paul Lauterbur were awarded with the Nobel Prize (Medicine/Physiology) for applying the fundamental discoveries of NMR to medical imaging.

### **1.1 Basic principles of MRI**

To introduce the basic concepts and terminology, the basic principles of magnetic resonance imaging are briefly described below. For a thorough description of the physical principles, readers should be referred to standard MRI textbooks, e.g. (9)

### 1.1.1 Nuclear spin

For MRI to provide tomographic images a strong magnetic field is required combined with application of smaller local fields (gradients) and electromagnetic transmit- and receive-coils. The technique utilizes electromagnetic properties of specific nuclei naturally abundant in body tissues. So far the hydrogen nucleus,  $H^+$  (which is a proton), is the most interesting nucleus because of its high abundance (about 2/3 of body weight is water), and because it gives the strongest signal. The proton is a charged particle with spin, and exhibits the electromagnetic properties of a dipole magnet. In the absence of an external magnetic field, the directions of the protons are random and thus no net magnetization is produced. When body tissue is placed in an external magnetic field  $B_0$ , the direction of the protons is either parallel or anti-parallel with  $B_0$ . They not only rotate about their own axis but also precess about the axis of the external magnetic field with a specific rate. This can be expressed by the Larmor equation:

$$\omega_0 = \gamma B_0$$

where  $\omega_0$  is the angular precessional frequency,  $\gamma$  is the gyromagnetic ratio specific for the nuclei, and  $B_0$  is the strength of the external magnetic field. The gyromagnetic ratio is a proportionality constant dependent on the kind of nucleus, where the hydrogen nucleus has the highest gyromagnetic ratio. A net magnetization  $M_0$  is produced in the same direction as  $B_0$  because of an excess of parallel protons compared to anti-parallel protons. The direction of  $B_0$  and  $M_0$  is defined as the z-axis in a 3-dimensional coordinate system.

An electromagnetic wave, a pulse of radiofrequency (RF) energy, with the same frequency as the precessing protons, is then applied to the body tissue. This generates a resonance condition which excites the protons. As a consequence, the  $M_0$  vector along the z-axis is flipped into the x-y plane. There is now a magnetization vector,  $M_{xy}$ , in the x-y plane with an initial value equal to  $M_0$ , precessing around the axis of the external magnetic field. A receiver coil placed in the xy plane measures the net magnetization as the oscillating nature of  $M_{xy}$  induces a current in the coil. This measured signal, which is referred to as the free induction decay (FID), will reduce or *decay* due to proton relaxation processes which are further described below. The time between each successive excitation pulse is termed the repetition time, TR. For each RF pulse, the MR signal is sampled after a given delay ( $\sim$ ms), which is referred to as the echo time, TE. The MR signal may be manipulated or sampled in


many different ways by multiple combinations of pulses and sampling processes, referred to as pulse sequences.

### ***1.1.2 Intrinsic contrast mechanisms***

The versatility of MRI is achieved by exploiting contrast mechanisms to generate images. The contrast mechanisms in MR imaging are based on tissue-specific parameters, utilized with appropriate pulse sequence choice, sometimes with the application of a contrast agent. Only the intrinsic and static contrast mechanisms T1, T2/T2\* and proton density (PD) will be presented below.

#### **T1 relaxation time**


The protons are in a state of high energy when excited and when the RF pulse is turned off, they return to their equilibrium state which is by definition the lowest energy state of the two possible. The protons release all their excess energy and realign with the axis of the external magnetic field  $B_0$ . Hence, the  $M_z$  vector will grow with a time constant T1, which is called the longitudinal relaxation time or the spin-lattice relaxation time. T1 is tissue dependent and is one of the main contrast parameters in MRI. The chemical environment the protons experience in the tissue determines the rate of the relaxation of the protons (T1 relaxation rate,  $R_1$ , is defined as  $1/T1$ ). Free water molecules have a longer relaxation time than bound or structured water molecules, resulting in different T1 values for the different types of tissue. Fat and free water, such as the cerebrospinal fluid (CSF), are the two contrary tissues when it comes to T1 relaxation rate. Strong tissue contrast on T1-weighted images is obtained by choosing an optimal TR that maximises the contrast between tissues with a slightly different T1 value (Figure 1). To obtain images with a strong T1 contrast, a short TR and a short TE is normally chosen. In addition to being tissue-specific, the T1 relaxation rate is also dependent on field strength, with shorter T1 at lower field strengths. Thus, the TR must be optimised for the field strength applied.

**Figure 1: T1 contrast**

The figure shows a T1-weighted image acquired on a 1.5 T system. The graphs to the left illustrate the tissue specific speed of T1 (recovery of  $M_z$ ) and T2 relaxation (decrease of  $M_{x,y}$ ), and the optimum TR and TE for gray and white matter differentiation on T1-weighted images. Adapted from (1).

### T2 relaxation time

One of the other main contrast parameters is the T2 relaxation time. When the RF pulse is applied to the system and the longitudinal magnetic vector is flipped into the xy plane, all the rotating protons are in the same phase and the net magnetization  $M_{xy}$  has its maximum value. Immediately after the RF pulse is turned off the protons will start to dephase and  $M_{xy}$  starts to decrease with a time constant T2. This effect is primarily related to the intrinsic field variations due to adjacent protons, and is therefore referred to as spin-spin relaxation time, or transverse relaxation time, since it takes place in the transverse (xy) plane. The effect of the spin-spin interaction depends on the proximity of the protons to each other. In water, the protons are separated more widely than in solid tissue and thus the dephasing effect is not that prominent in water as in solid tissue. T2-weighting of an image is emphasised by using long TR and long TE (Figure 2). The second cause of dephasing is due to external magnetic field in-homogeneities. This makes the protons at different locations precessing at different frequencies because each proton is exposed to a slightly different external magnetic field strength. When this cause of dephasing is emphasised, the image is T2\*-weighted.

**Figure 2: T2 contrast**

The figure shows a T2-weighted image acquired on a 1.5 T system. The graphs to the left illustrate the tissue specific speed of T1 (recovery of  $M_z$ ) and T2 relaxation (decrease of  $M_{x,y}$ ), and the optimum TR and TE for gray and white matter differentiation on T2-weighted images. Adapted from (1).

---

## Proton density

One of the simplest forms of MR contrast is PD imaging. The net magnetisation of each voxel is composed of individual spins within that voxel. As the name implies, tissue contrast is provided based on the sheer number of protons within a voxel, which differs across tissue types. To maximise the proton density weighting of an image, the effects of T1 and T2 are minimised by using long TR and short TE.

## 1.2 MR contrast agents in neuroimaging

In the early days of MRI, it was believed that there was no need for external contrast agents in MR examinations. However, in the late eighties, the development of MR contrast agents started in order to improve the definition of the internal structures and function of the body, thereby making the method even more sensitive and the diagnosis more specific (10). MRI is very sensitive to the effects of the contrast agent, allowing a significant reduction in contrast agent dose compared to what is used in conventional X-ray imaging modalities. Contrary to radiographic contrast agents, which change the local density and thus create a direct change of the contrast in the image, MR contrast agents induce a change in the local magnetisation in its surrounding tissue. Hence they have an indirect effect on the image contrast. It is the magnetic properties of the contrast agent that is explored by MRI, and contrast agents affect hydrogen magnetisation in two primary ways i) through direct relaxivity effects (changing T1 and T2 relaxation rates of the tissue) or ii) through indirect susceptibility effects (11). The contrast agent's ability to induce signal changes through direct interactions with protons in surrounding tissue is described by its relaxivity. The increase in relaxation rate ( $R_1 = 1/T1$  or  $R_2 = 1/T2$ ) per unit concentration of tracer (i.e. contrast agent) is the relaxivity  $r_{1,2} = (R_{1,2b} - R_{1,2a})/\Delta C$ , where  $r_{1,2}$  is measured in  $\text{mM}^{-1} \text{s}^{-1}$ . Susceptibility relaxation is caused by differences between the paramagnetic contrast and the surrounding tissue protons. This contrast mechanism influences relaxation effects in tissue at longer distances than dipolar relaxation. Due to its sensitivity to field inhomogeneities, it is primarily the transverse relaxation rate that is affected by susceptibility relaxation (12).

Most contrast agents can be used to produce both effects, but in general one effect dominates, depending on the concentration of the contrast agent, MR imaging techniques, and tissue distribution properties. Contrast agents are often grouped into paramagnetic or

superparamagnetic contrast agents based on their magnetic properties. At present, paramagnetic contrast agents are the most frequently used and have become an integrated part of the daily practise of MRI (13, 14). Contrast agents are also termed positive and negative contrast agents, due their dominating effect on the signal on the MR image (i.e. signal enhancing due to dominating T1 effect or signal attenuating due to dominating T2 effect, respectively). Furthermore, MR contrast agents can be grouped according to their biological distribution; extracellular fluid-contrast agents (ECF-agents), blood-pool agents or targeted/tissue-specific agents. Low-molecular contrast agents are classified as ECF-agents as they rapidly equilibrate between the intravascular and extravascular spaces. However, the brain is different from the body as the contrast agent is retained intravascularly in the case of an intact blood-brain-barrier (BBB). Contrast agents for cellular MR imaging are further described in section 1.7.1.

### **1.2.1 Paramagnetic contrast agents**

Gadolinium (Gd) is a lanthanide metal with paramagnetic properties and is the most commonly used compound in MR contrast agents. As Gd is toxic, the compound is chelated, and Gd-based contrast agents are regarded as safe and are well tolerated when injected intravenously (i.v.) (15). First generation, or low-molecular weight Gd-based contrast agents (~500 Da), such as Gd-DTPA (Magnevist, Schering/Berlex), Gd-DTPA-BMA (Omniscan, Amersham Health), Gd-DO3A-butrol (Gadovist, Schering) and GdHP-DO3A (ProHance, Bracco) share similar distribution and enhancement properties at lower field strengths (16) ( $r_1$  ranging between and 3.4-3.8 mM<sup>-1</sup> s<sup>-1</sup> at 1.0 T). The typical relaxivity dependence on the magnetic field for Gd-compounds is a maximum followed by a decline as the field strength increases. The Gd-based agents are regarded as positive contrast agents as their predominant effect is shortening of the T1 relaxation time, seen as hyperintensity on the MR image.

In the case of highly malignant brain tumours, the contrast agent leaks out into the tumour tissue due to disruption of the BBB, and the regions with contrast enhancement may correspond well with the solid tumour mass. However, Gd-enhancement is relatively non-specific. For instance, it may be difficult to differentiate between radiation necrosis and recurrent tumour after radiation therapy (17). More innovative developments in MR contrast agent design have led to the emergence of new second generation Gd-based compounds which differ from currently available agents in possessing markedly increased *in vivo* T1

---

relaxivity. Generally, second generation contrast agents also have a higher molecular weight than the first generation Gd-based agents, and are regarded as blood-pool contrast agents. The use of high relaxivity agents in diagnosis of brain tumours may improve detection and delineation of the tumours, hence improving the sensitivity and differential diagnostic processes (16). Macromolecular contrast agents may also give a better correlation between histologic tumour grade and permeability parameters assessed by dynamic contrast enhanced (DCE) imaging as demonstrated in animal models using albumin-Gd-DTPA-30 (18). Gadomer (Schering AG, Germany) has also proved to be a promising contrast agent for early detection of treatment effects or residual disease in tumours (19-21) and is suggested as an important tool in future clinical settings (22). The role of MR imaging in the diagnosis and follow-up of brain tumours is further described in section 1.6.

### ***1.2.2 Superparamagnetic contrast agents***

Iron-oxide or dysprosium based contrast agents are regarded as superparamagnetic contrast agents. They are often termed negative contrast agents as their predominant effect is signal attenuation due to shortening of the T2 relaxation time or susceptibility effect. Superparamagnetic iron-oxide (SPIO) or ultrasmall SPIO (USPIO) are the most commonly used negative contrast agents and the T2 and T1 relaxivity of a typical (U)SPIO is substantially larger than the relaxivity of paramagnetic compounds (23). The observed effects on signal intensity depend on several factors, including particle composition, particle size, and concentration within a voxel. Most (U)SPIOs are classified as blood-pool contrast agents and do not play a significant role in neuroimaging and brain tumour diagnosis yet. However, the potential of using USPIOs in this regard has been investigated. Enochs and co-workers observed that compared to Gd-chelates, long circulation SPIOs can provide prolonged delineation of the margins of human brain tumours on MR images, which has implications for the targeting of diagnostic biopsies and the planning of surgical resections (24). Others have reported that USPIOs can not replace Gd-based contrast agents in the diagnosis of brain tumours as the tumour volumes visualised on USPIO contrast enhanced T1-weighted images do not correlate with contrast enhancement with Gd-based agents (17). In a study where the tumour delineation was evaluated by T2 pulse sequences, demarcation of the tumour border was difficult due to a blooming effect, but USPIOs seemed to enhance delineation of neovascularisation (17). Zimmer and co-workers reported that phagocytosis of

monocrystalline iron-oxide particles (MION) by glioma cells has been observed in a rat glioma model, which permitted determination of tumour margins (25). The role of (U)SPIOs in cellular MR imaging is described in 1.7.1.

### **1.3 Primary brain tumours**

Gliomas are tumours derived from glial cells (i.e. astrocytic, oligodendrocytic, ependymal or mixed origin). Astrocytoma is the most frequently observed and accounts for approximately 65% of primary brain tumours. The most malignant of these, is the glioblastoma multiforme (GBM). There are regional variances in the tumour incidence, with a higher frequency in Europe, Australia and North-America (26). Within the Western world there are usually around 6-11 new cases of primary intracranial tumours reported per 100.000 capita in men and 4-11 in women, with an increasing frequency with increasing age (26). There has been a growing number of gliomas reported per year in industrialised countries, which has been attributed to the development of high-resolution neuroimaging techniques such as computer assisted tomography (CT) and MRI. In the Nordic countries, the increase in incidence was confined to the late 1970s, which coincided with the introduction of improved diagnostic methods (27).

#### ***1.3.1 WHO classification***

In keeping with the degree of aggressiveness, gliomas are divided into four grades according to their biological behaviour. As different gliomas show a heterogeneous histological appearance, the final classification includes both histological features and degree of malignancy or anaplasia. At present, the classification system of the World Health Organization (WHO) is used. Gliomas of astrocytic origin (astrocytomas) are classified into pilocytic astrocytoma (Grade I), low-grade astrocytoma (Grade II), anaplastic astrocytoma (Grade III), and GBM (Grade IV) (28). The significant indicators of anaplasia include nuclear i) atypia, ii) brisk mitotic activity, iii) increased cellularity, iv) vascular proliferation, and v) necrosis (see Table 1.3.1). Two distinct types of GBMs are recognised, based on their clinical history. Primary GBMs are characterised by a very rapid development of clinical symptoms, where approximately 50 % of the patients have a history of less than six months, whereas secondary GBMs evolve from progression of low-grade astrocytoma and anaplastic



astrocytoma in the course of several years (mean 4-5 years) (29). Primary GBMs tend to develop in older patients (mean age 50-55 years), while secondary GBMs have a peak at a lower age (i.e. 40 years) (29).

**Table 1:** The WHO classification system of astrocytomas

WHO grade	WHO designation	Histological criteria
I	Pilocytic astrocytoma	None of the below criteria
II	Astrocytoma (low-grade diffuse)	Nuclear atypia
III	Anaplastic astrocytoma	Nuclear atypia and mitotic activity
IV	Glioblastoma multiforme	Nuclear atypia, mitosis, endothelial proliferation and/or necrosis

Neurological symptoms from glioma development depend mainly on the location of the tumour within the brain. However, each glioma subtype has a specific prognosis that dictates the clinical management. The length of the patient's clinical history and the chance of a long, recurrence-free survival are closely related to the histopathological characteristics of the neoplasm. Despite advances in surgical and clinical neuro-oncology, mortality rates are still high and GBM patients have a mean survival of less than a year after diagnosis. Also, higher age is the strongest prognostic factor of poor survival of these patients (30).

### ***1.3.2 The cellular origin of gliomas***

#### **The somatic mutation hypothesis**

The predominant theory about the origin of gliomas is that these tumours develop from somatic mutations in differentiated mature astrocytes or oligodendrocytes, which subsequently undergo series of transformation steps to a less differentiated phenotype (31). However, the somatic mutation hypothesis does not explain the perplexing paradox that whilst normal glial cells tend to be morphologically homogeneous, malignant gliomas, which are presumed to be of clonal lineage, display striking cellular heterogeneity. Furthermore, the prognostic power of the WHO classification nomenclature relies mostly on the tumour architectural features (28) (Table 1). There exists an inconsistency when lower grade gliomas, exhibiting endothelial proliferation, are not classified as GBMs. Moreover,

not only are gliomas heterogeneous in their cellular morphology, but individuals with malignant gliomas show marked variations in response to current treatment modalities.

### **The cancer stem cell hypothesis**

An alternative hypothesis posits that subpopulations of cancer cells within tumours reflect the developmental hierarchy of the normal tissue from which the tumour arose. This model suggests that tumours are driven and maintained by a small subpopulation of cells that have the capacity to self-renew and to generate a more differentiated progeny, which make up the tumour mass (32, 33). This cell population has been termed cancer stem cells (CSC), tumourigenic cancer cells, or tumour-initiating cells. Brain tumours could thus arise from transformed neuroepithelial stem cells or glia precursor cells, which show capabilities of self-renewal by asymmetric cell division. This may lead to a variety of brain tumour types that harbour cell types that show different stages of cellular differentiation. *In vitro* analyses of brain tumour cells sorted for CD133 expression (cell surface protein which is a marker for stem cells such as NSCs), indicated that the capacity of self-renewal and proliferation exclusively resides in the minority of CD133<sup>+</sup> cell fraction, which may imply that this surface protein may be a new cell surface marker for brain tumour stem cells (BTSC) (34). *In vivo* experiments conducted by the same group showed that only the CD133<sup>+</sup> cells were capable of tumour initiation in the NOD-SCID (non-obese diabetic, severe combined immunodeficient) mouse brain (35). The identification of brain tumour initiating cells may provide insights into human brain tumour pathogenesis, giving strong support to the CSC hypothesis as the basis for many solid tumours, and establishes a previously un-identified cellular target for more effective cancer therapies (32, 36).

### **1.3.3 Brain tumour biology**

To describe the biological properties of brain tumours in detail is beyond the scope this thesis. However, some key features such as invasion and angiogenesis will be presented in the following sections.

#### **Diffuse invasion**

Primary brain tumours are characterised by a diffuse local invasion of migrating tumour cells that leads to a poor demarcation of the neoplasm. Invasion of tumour cells into normal

tissue is thought to be a multi-factorial process involving changes in cell morphology, cell-cell and cell-extracellular matrix (ECM) adhesion interactions, and remodelling of the extracellular space by proteases (37, 38). Migratory tumour cells exhibit a different phenotype from non-migrating tumour cells as they may show reduced proliferation and loss of normal cell regulatory mechanisms (38). These migrating cells represent a therapeutic challenge as they give rise to recurrent tumours following surgical and chemo- and radiotherapeutic interventions as further described in section 1.4.

### **Angiogenesis**

Angiogenesis plays a key role in the pathogenesis of tumours and is essential for tumour growth (31). Without angiogenesis, most solid tumours can not grow beyond 1-2 mm in diameter. Normally there is a fine balance between stimulators and inhibitors of angiogenesis but in malignant tumours, pro-angiogenic factors prevail, where vascular endothelial growth factor (VEGF) is among one of the key stimulators of endothelial cell proliferation (31, 39). The tumour tissue can recruit its blood supply through different pathways such as i) vascular sprouting from pre-existing host vessels in the surrounding normal tissues, ii) cooption of pre-existing host vessels, i.e. the tumour cells survive under the existing host vasculature, and iii) recruitment of circulating bone-marrow derived endothelial cells that develop new blood vessels within the tumour (39, 40). Angiogenesis is usually linked to tumour aggressiveness. For gliomas there is a clear increase in angiogenesis from low- to high-grade tumours (41).

## **1.4 Conventional and experimental treatment strategies**

The current standard treatment approach for patients with high-grade gliomas consists of surgical resection, preferably a gross-total resection of the solid tumour mass, followed by radiotherapy and/or chemotherapy (42, 43). In general, the effect of treatment on the overall prognosis has been limited, and the expected postoperative survival for GBM patients is less than a year (30). GBMs are difficult to treat and represent a special treatment challenge due to the following characteristics (44): i) invasive growth and spread of malignant cells into brain parenchyma, ii) intrinsic resistance to conventional therapy, iii) the localisation of tumours may preclude surgical resection, iv) limited capacity of the brain to repair itself, v)

variably disrupted BBB complicating effective drug-delivery, vi) tumour capillary leakage with resulting peritumoural oedema and intracranial hypertension, and vii) neurotoxicity as a result of aggressive treatment procedures. At present, there is a need for new and more effective therapeutic modalities for malignant brain tumours, and a better understanding of the biological properties of the tumour is essential. It may be that recent advances in neuroimaging will give some answers regarding biological parameters related to a treatment response. With a continued improvement in treatment and imaging techniques, there is a hope that GBM may be a controllable disease. Research in gene therapy, antiangiogenic therapy, and immunotherapies holds some promise (45) but to address these issues in detail is beyond the scope of this thesis.

#### ***1.4.1 Neural stem cells as a potential treatment modality***

The discovery and characterisation of a pool of neural stem cells (NSC) that persists into adulthood and retain the capacity to self-renew and differentiate, has provided new avenues for researchers to investigate mechanisms of brain tumour formation and treatment response. To date, the neuro-biological findings using stem cells have been applied i) towards a better classification of tumours to hopefully improve prognostics (46) and ii) as a potential vehicle to improve delivery of therapeutic agents into brain tumours (47-50). Due to the inherent pluripotency of NSCs, another potential role of such cells may be to repair tissue damage caused by the brain tumours in situ and the neurological impairment that is frequently associated with traditional cancer treatment approaches (51, 52).

The main characteristic of NSCs that make them attractive vehicles for targeted delivery, is their tropism towards neoplasms. Aboody and colleagues were the first to describe that modified exogenous NSCs injected at various sites (both ipsilateral and contralateral hemisphere to the brain tumour, into the cerebral ventricles, and into systemic circulation) had the capability to migrate over long distances towards the glioma. They also reported that NSCs positioned themselves juxtaposed to glioma cells migrating away from the main tumour mass (47), indicating that NSCs may mimic the migratory pattern of infiltrating glioma cells (48). This can be exploited to target minute brain metastases and infiltrating malignant satellites after tumour resection (53). NSCs also have the potential to integrate into the host brain without disrupting normal tissue function (53). Exogenous NSCs may be clonally expanded in tissue culture, providing a renewable supply of material for

transplantation. As they can be propagated for long periods, it also makes them amenable genetic manipulation. Several groups have in recent years reported promising results using NSC-based gene therapy in animal models of high-grade gliomas and different therapeutic strategies have been developed, resulting in reduced tumour growth (47, 49, 54-56) and extended survival (48, 57, 58). An intrinsic tumour-inhibitory effect of neural stem cells has also been reported when NSCs were co-inoculated with glioma cells (59) or grafted into established gliomas (48). NSCs may represent a vehicle for the delivery of genes and proteins to brain tumours and the use of such cells also represent a targeted delivery approach for substances that require distribution throughout the brain.

#### ***1.4.2 NG2 progenitor cells as a potential target for brain tumour therapy***

Neuron-gial 2 (NG2)-expressing cells are the largest proliferating cell population in the adult CNS (60). NG2 is a highly conserved chondroitin sulfate transmembrane proteoglycan that is expressed on oligodendrocyte precursor cells of the developing and mature CNS (61). The function of NG2-expressing cells is largely unknown but the cells are activated to proliferate following different forms of CNS damage, such as mechanical injury, excitotoxicity, viral infections and tumour development (62). Chekenya and co-workers have previously reported increased NG2 expression in 13 out of 18 human GBMs. NG2 was found to be expressed on both the tumour cells and by the associated vasculature (63). NG2 has also been shown to increase tumour cell proliferation *in vitro*, and to promote angiogenesis *in vivo*, which predisposes animals to poorer survival outcomes by binding angiostatin (64, 65). High NG2 expression also coincides with resistance to chemotherapy, where it may be a novel regulator of chemoresistance (Chekenya et al, submitted). Thus, NG2 plays a major role in tumour-stroma activation through alterations in cellular adhesion, migration, proliferation, and vascular morphogenesis, and increased NG2 expression correlates with an aggressive disease course (63). NG2 is expressed on the cell surface, and due to its putative role in tumour-host interactions, it is suggested as an attractive candidate for targeted brain tumour therapy (66-69).

## 1.5 Experimental glioma models

There is a considerable need for appropriate animal models in experimental neuro-oncology (70). By using valid model systems, the genetic events leading to oncogenesis can be studied, possible targets for tumour therapy can be identified, and knowledge about tumour angiogenesis and invasion can be provided (71). Another rationale for using *in vivo* animal models is to assess the efficacy of innovative treatment approaches. Rat brain tumour models have extensively been used since the mid 1970's (70). Initially, the tumours were induced by using various neurotrophic carcinogens, later cell lines were generated from human GBMs and then transplanted into the CNS of immunodeficient rats (71). The advantage of cell line-based models is high efficacy with reproducible growth rate, survival time, and tumour location. Moreover, immortalised cell lines are readily expanded *in vitro*, allowing almost unlimited amounts of tumour material for experimental use. A major disadvantage of using cell line-based systems is genetic and phenotypic deviations caused by the tissue culture environment. To circumvent this problem GBM models have been initiated by short term cultures of the patient's biopsy material in the form of multicellular spheroids without previous passaging in monolayers (72). When transplanted into the rat brain, tumours will develop that show several biological features reflecting the original tumours *in situ* such as extensive cell invasion and angiogenesis (72, 73). Another attractive approach for studying brain tumours and treatment modalities is the use of transgenic animals but such models will not be addressed in the current work.


## 1.6 MR imaging of brain tumours

The crucial role of neuroimaging in neuro-oncology include refinement of pre-operative differential diagnosis, precise anatomical localisation, detection of response to treatment and tumour progression, and recognition of treatment related side-effects (74). Cranial CT and MRI are widely used for primary diagnosis of brain tumours (75), but MRI is the method that provides the most comprehensive imaging information needed for patient diagnosis and treatment evaluation, due to its high spatial resolution and high tissue contrast (75, 76).

### 1.6.1 Conventional MR imaging

The diagnosis of brain tumours by MRI is usually based on basic pre-contrast T1-weighted and T2-weighted images and post-contrast T1-weighted images in one or two orthogonal directions (76). Standard T1- and T2-weighted sequences detect brain tumours with high sensitivity (75). The recognition of neoplasms is mainly based on the mass effect and signal alterations caused by pathological processes due to tumour formation and progression. Most tumours appear as hypointense on pre-contrast T1-weighted images (Figure 3 A) and hyperintense on T2-weighted images (Figure 4 B) due to elongation of T1 and T2 relaxation times caused by the presence of vasogenic oedema and/or tumour infiltration (75). On PD-weighted images, brain tumours appear as hyperintense (75) (Figure 4 A). I.v. injections of a positive contrast agent will in cases of a disrupted BBB cause a signal enhancement on T1-weighted images due to leakage of the contrast agent from blood vessels into tumour tissue (Figure 3 B-D). Secondary effects of a tumour, such as necrosis, haemorrhage, and formation of cysts, modulate the appearance of tumours on MR images, which may make them more conspicuous but at the same time more easily to be mistaken for non-neoplastic lesions (76).


**Figure 3:** T1-weighted MR images of a patient with GBM



*The figure shows T1-weighted MR images of a 53 year old male patient with GBM, acquired with a 3T GE Signa Excite (Haukeland University Hospital, images kindly provided by Turid Randa and Roger Barndon). A) a pre-contrast axial slice showing a hypointense region in the frontal lobe. B) corresponding slice acquired after i.v. injection of a Gd-based contrast agent, showing a non-enhancing central necrosis surrounded by a ring enhancement. C) and D) coronal and sagittal slices of the same patient, respectively.*

These conventional MR imaging techniques are not sufficient for the grading and specification of brain tumours but there are correlations between the appearance on MR images and the histological features of gliomas, as a set of various MRI acquisition parameters give a characteristic pattern of each tumour depending on tumour type and grade (74, 75). Low-grade diffuse astrocytomas (WHO grade II) most often appear as homogenous hyperintense on T2-weighted images and peritumoural oedema is usually not present. T1 post-contrast images do not give any evidence of abnormal contrast enhancement, which indicates absence of tumour angiogenesis in these tumours. WHO grade III gliomas (anaplastic astrocytomas) show typically nodular areas of contrast enhancement, moderate expansion of affected brain regions due to increased cellularity, and in some cases vasogenic oedema surrounding the main tumour mass (74). GBMs (WHO grade IV) show signs of widespread peritumoural oedema and tumour infiltration, appearing as strongly hyperintense areas on T2-weighted images. A distinct mass effect which may cause a mid-line shift visible in all imaging sequences and a heterogeneous signal enhancement on T1 post-contrast images are other typical GBM imaging characteristics. Areas of necrosis appear as hypointense on T1 post-contrast images and if cystic, strongly hyperintense on T2-weighted images. The presence and degree of tumour necrosis visible on MR images correlates with clinical outcome and survival of patients with GBM (77).

**Figure 4:** PD-weighted, T2-weighted and T2 FLAIR images of a patient with GBM



*The figure shows MR images of the same patient as in figure 3 (images acquired at the same time-point). A) PD-weighted image with a modest hyperintense region, B) T2-weighted image where the tumour and the peritumoural oedema appear as hyperintense, C) the tumour region appear as hyperintense on the T2-weighted FLAIR image. The MR images are kindly provided by Turid Randa and Roger Bandon at Haukeland University Hospital.*

Another MR imaging technique, suggested as a valuable tool for tumour diagnosis and grading, is the fluid attenuated inversion recovery (FLAIR) sequence (78) (Figure 2 C). The



FLAIR sequence is either T1- or T2-weighted, with an inversion recovery which eliminates the signal from cerebral spinal fluid (CSF). T2-weighted FLAIR is extensively used for diagnosis of for example multiple sclerosis. In the case of low-grade astrocytomas, lesions have been demonstrated with greater conspicuity than with conventional T2-weighted sequences (79). T2-weighted FLAIR can also be used to differentiate the tumour mass from oedema in cases where the solid tumour induces a strong hyperintensity in T2-weighted images (78). Recent studies have reported that post-contrast FLAIR sequences due to a marked T1 effect, may improve the depiction of brain tumours by a distinct contrast enhancement, resulting in higher tumor-to-background contrast ratio compared with standard imaging techniques (80, 81).

### ***1.6.2 Functional MR imaging of brain tumours***

Advances in MRI allow studies of physiological processes in time and analysis of tumour tissue properties such as perfusion, angiogenesis and water mobility within the tissue. Morphologic imaging may not always meet the need for characterising biological processes, and the above mentioned parameters may serve as surrogate markers for these (82). Functional MRI methods such as dynamic contrast enhanced T1-weighted imaging (DCE-MRI), dynamic susceptibility contrast imaging (DSC-MRI), and diffusion weighted imaging (DWI) are presented below.

#### **DCE-MRI and DSC-MRI**

Quantification of the tumor angiogenesis status might serve both as a prognostic index for the specific tumour examined and as a tool for monitoring effects of antiangiogenic or antivascular treatment (83-86). To assess angiogenesis, DCE-MRI or DSC-MRI can be applied to quantitatively characterize certain tumor microvascular properties, including richness of vascular supply and vascular endothelial leakiness or permeability.

DCE-MRI is performed in order to achieve non-invasive assessment of vascular permeability. After baseline images are acquired, the contrast agent is injected i.v. and the time course of the tracer is followed by dynamic T1-weighted imaging. T1-weighted kinetic enhancement curves have three distinct phases; the up-slope, maximum enhancement and the wash-out. It is generally recognised that the up-slope gradient in tumours is highly dependent on tissue perfusion and permeability. Maximum enhancement is related to the

total uptake of the contrast medium in the extravascular extracellular space (EES) and the wash-out rate is associated with the decrease of tissue contrast agent concentration and is related to vascular permeability (83). Depending on the molecular size of the contrast agent used, the acquisition time needed to follow the course of the tracer varies from 3-4 to 30 minutes with a typical temporal resolution of 10-30 seconds.

Quantification of microvascular permeability parameters is done by implementing pharmacokinetic models that estimates the permeability of the tracer as a surrogate marker. Three major models have been reported for leakage studies (87-89). The methodologies for permeability quantification have been reviewed and a consensus has been reached (90). Common parameters to describe permeability are  $K^{\text{trans}}$  and  $k_{\text{ep}}$ , where the former is related to the product of vessel surface and vessel permeability, and  $k_{\text{ep}}$  reflects transfer from the EES to the plasma. Newly formed vessels exhibit transendothelial leakage and the rate of diffusion of the tracer from the vessels is a reflection of the integrity of the microvessel wall. As a consequence of high angiogenic activity, high-grade tumours may have more leaky vessels (41). Increased vessel permeability is related to the histological grade of the glioma, and positive correlations between vascular parameters assessed by DCE-MRI and glioma aggressiveness (91, 92) and length of patient survival have been reported (92). Parametric maps of permeability transfer constants and blood volume may display regional differences in the distribution of kinetic parameters within brain tumours (91, 93, 94), and provide unique insights into tumour structure, function and response to treatment. DCE-MRI is increasingly being used to evaluate antiangiogenic and antivascular therapy agents in early stage clinical trials, and guidelines to perform clinical trials effectively with DCE-MRI have been made (85, 86).


Dynamic T2/T2\*-weighted sequences can be designed to be sensitive to the vascular phase of contrast agent delivery. Signal changes reflect tissue perfusion and cerebral blood volume (CBV). In recent years, assessment of vascular permeability has also been achieved by DSC-MRI, and a positive correlation between tumour aggressiveness and vessel leakiness using this method have been reported (95-97). CBV obtained with DSC-MRI can be used to predict the histopathological grade of tumours as CBV is generally higher in high-grade gliomas (grade III and IV) than in grade II gliomas (95, 98, 99). DSC-MRI is mainly carried out by rapid T2/T2\*-weighted acquisitions following the first pass of a contrast agent bolus through the microcirculation of the region of interest (ROI), with a typical temporal

resolution of 1-2 seconds. As the contrast agent follows the blood through the capillaries, it induces a susceptibility effect seen as signal attenuation on the T2/T2\*-weighted images. To date, MR measurements of CBV have been evaluated for assessment of tumour aggressiveness, selection of biopsy location, evaluation of treatment response, and differentiation of recurrent tumour from treatment effects such as radiation necrosis (82).

## DWI

DWI is sensitive to the microscopic Brownian movement of water molecules in tissues. Recently, DWI has gained considerable interest in the field of brain tumour imaging. Even though there are conflicting results regarding the clinical implications of DWI and quantification of the apparent diffusion coefficient (ADC), a general assumption is that necrotic or cystic regions of a tumour appear to be hypointense on DW images. An increased ADC in these regions has been reported (100-102), which may be used to differentiate brain tumours from brain abscesses. Lower tumoural ADC values have been linked to high-grade gliomas, whereas higher ADC values indicated low-grade gliomas (103, 104). Replacement of the normal tissue with numerous tumour cells is likely to restrict the diffusion of water, and a reduced ADC has been found in regions with higher cell densities (105). Also, components of the extracellular matrix may influence the ADC values in gliomas. A relationship between hyaluronan levels in the extracellular matrix and ADC values has been proposed for both high-grade and low-grade gliomas (106). Regions with vasogenic oedema have revealed increased diffusion properties compared to normal and tumour tissue (107, 108) (Figure 5). Pre-clinical settings have also shown that diffusion MRI is an effective tool for evaluation of treatment response and development of drug resistance (109, 110) and may serve as an indicator of survival (110).

**Figure 5:** ADC map of a patient with GBM



*The figure shows a parametric ADC map of the same patient as in Figure 3 and 4. The ADC map reveals an increased diffusion in the tumour region, indicating high degree of vasogenic oedema. The images are kindly provided by Turid Randa and Roger Barndon, Haukeland University Hospital.*

## 1.7 Cellular MR imaging

Cellular and molecular imaging is a relatively young but rapidly emerging field. In contrast to conventional diagnostic imaging, it aims at identifying cellular or molecular abnormalities that represent the basis of disease, rather than to image the end effect of these alternations (111). In addition to MRI, a broad range of imaging modalities provides possibilities to assess information related to physiology and pathology at a microscopic level, such as magnetic resonance spectroscopy (MRS), positron emission tomography (PET), single photon emission tomography (SPECT), optical imaging (OI), and bioluminescence imaging (BLI).

The boundary between cellular and molecular imaging is not distinct and areas of overlap exists. In this context MRI can be classified into two categories, i.e. cellular MRI and molecular MRI. Cellular MRI is less specific than molecular MRI, and can be defined as the non-invasive and repetitive imaging of targeted cells and cellular processes in living organisms, whereas molecular MRI refers to imaging of subcellular components in living organisms (112). The development of *in vivo* cellular imaging by MRI allows the repeated measurements of specific cell loss, cell migration and regeneration (113). Until recently, *in vivo* studies of particular cell populations has been precluded by lack of appropriate technology as snapshot images from *ex vivo* histological sections have provided the only source to broaden our understanding of cellular dynamics. MRI-based tracking of specific cell populations in animals was first described in 1990 (114) and has been further developed in a number of laboratories (115-122).

### 1.7.1 Contrast agents for cellular labelling

The imaging techniques used in cellular MRI do not differ from conventional MRI techniques as T1-weighted or T2-/T2\*-weighted sequences are commonly used to visualise cells. It is thus the target and not necessarily the technique that differentiates between the two. The cells must be labelled with MR contrast agents to distinguish them from the surrounding tissue. As the incorporation of MR contrast agents into cells renders them distinct from the surrounding tissue, it allows the *in vivo* identification and tracking of these targeted cells by MRI. Cells can either be labelled *in vitro* prior to transplantation, or *in vivo* by contrast agent injection into the blood stream or the ventricles of the brain (113).

---

### **Iron-oxide based contrast agents**

Superparamagnetic iron-oxide (SPIO) or ultrasmall SPIO (USPIO) are the most commonly used contrast agents for cell labelling, and the predominant effect of iron-oxide labelled cells is signal attenuation on T2- or T2\*-weighted images. The advantage of (U)SPIO particle labelling is mainly due to i) the largest change in signal intensity per unit of metal, ii) iron is biodegradable and can therefore be re-used or recycled by cells, iii) their surface coating, mainly dextran, allows straightforward chemical linkage between functional groups and ligands, iv) they can be detected by light and electron microscopy using staining techniques such as Prussian Blue, and v) their magnetic properties can be changed by varying their size. Recently, several groups reported *in vivo* tracking of single cells by incorporation of micrometer-sized iron-oxide particles (MPIOs) (123) or SPIOs (124, 125) into cells. This may lead to the early detection of cancer cell migration and more detailed information about stem cell migration and homing. Generally, a drawback of using (U)SPIOs for cell labelling is the blooming susceptibility artefact that involves an area substantially larger than the localisation of labelled cells, due to clustering of iron-oxide particles within the endosomes of the cells. The “black holes” induced by iron-oxide labelled cells also may be difficult to differentiate from signal loss due to susceptibility artefacts or imperfect pulse sequences (112). Moreover, distinguishing (U)SPIO-labelled cells from haemorrhage or necrosis is difficult on T2-/T2\*-weighted images due to similar signal characteristics and partial volume effects from surrounding tissue (126).


### **Gd-based contrast agents**

Contrast agents based on gadolinium or manganese represent an alternative labelling method, as these contrast agents are predominantly positive, and signal gain is easier to interpret than signal loss (113). Anderson and co-workers have reported promising results by using gadolinium-fullerenol compounds (Gd@C82) for cellular labelling and detection with MRI, also at high field strengths (126). The development of bimodal and multimodal contrast agents may be of added value; for instance can contrast agents containing a fluorescent dye provide the possibility to detect labelled cells with both MRI, fluorescent histology, and/or optical imaging (127, 128). Gadolinium Rhodamine Dextran (GRID) is an example of a bimodal contrast agent with both paramagnetic and fluorescent properties (127). GRID consists of a dextran polymer backbone, amino-modified (CH<sub>2</sub>)<sub>4</sub>-NH<sub>2</sub> with

covalently attached  $Gd^{3+}$  chelates and tetramethylrhodamine and with a total molecular weight of  $\sim 17$  kDa (Figure 6). GRID has been used for tracking grafted NSCs in stroke models (122, 129). The functional status of cells can be investigated by cellular incorporation of responsive contrast agents that only influence the signal intensity after enzymatic cleavage of the Gd-compound (130). Despite the versatility of Gd-based contrast agents, the magnetic momentum of paramagnetic compounds is smaller than for iron-oxide based agents, and hence a greater number of labelled cells is normally required to induce signal change (131).

Generally, for both paramagnetic and superparamagnetic compounds, the detection limits depend mainly on the concentration of the intracellular label and the spatial resolution of the MR image, which is largely determined by the external field strength. In the case of (U)SPIO, the detectability of labelled cells may be improved by modification of inhalation gases, as the intrinsic  $T2^*$  effect of large vessels is reduced by increasing the oxygen content (132).

**Figure 6:** The bimodal Gd-based contrast agent GRID (gadolinium rhodamine dextran)



*The figure shows the molecular structure of GRID (kindly provided by Professor Tom Meade, Northwestern, Evanston, Il.).*

### 1.7.2 Cellular uptake

For cellular imaging, contrast agents are generally taken up by cells through: i) phagocytosis, ii) receptors or receptor mediated endocytosis, or iii) pinocytosis. When cells are incubated for several hours with high concentrations of Gd-based agents in the growth

---

medium, pinocytosis has shown to be an important mechanism for cellular uptake (133). However, cells do not readily take up large compounds, but coating of particles with contrast agents can significantly improve cellular uptake (134, 135). By mixing the (U)SPIO formulation and the transfection agent, complexes of the two are formed through electrostatic interactions (136). The complex is taken up by the cells through formation of endosomes when added into the cell culture. Among commercially available (U)SPIO formulations used for cell labelling are Feridex, Endorem, and Sinerem (137).

Regardless of the labelling method or type of contrast agent used, labelling of cells should not impair cellular functions such as viability, proliferation, metabolism, migration and differentiation (113) and this issue should be thoroughly addressed prior to *in vivo* cellular imaging. Even though Gd-based contrast agents are chelated and non-toxic when administered, a potential biological degradation will expose the cells to toxic metals. Further work has to be done regarding the determination of long-term effects of cellular incorporation of iron-oxide- or Gd-based contrast agents (112), and the long-term stability of these compounds should be thoroughly investigated prior to clinical trials using cellular imaging with MRI.

### ***1.7.3 Implications of cellular MRI of the CNS using animal models***

Stem cell-based therapy is currently finding its translation from bench to bedside (138-141). As a part of this process, it is important to monitor the survival and differentiation of transplanted cells, as well as the accuracy of cell delivery. Cellular MRI is in the process of developing tools making this happen, and numerous studies have been performed to image the fate of transplanted stem cells and immune cells in different animal models. In this respect, prelabelling of cells with contrast agents is the most widely used method for cellular imaging, and enables the detection of grafted cells by MRI. The early visualisation of pathogenesis and evolution in an autoimmune condition, multiple sclerosis, was achieved by prelabelling T-lymphocytes and then tracking the grafted cells in mice by *in vivo* MRI (142, 143). The capacity of magnetically labelled transplanted oligodendrocytes and their precursor cells to (re)myelinate axons was demonstrated by Bulte and colleagues using cellular MRI (116). Jendelova and co-workers visualised the fate of transplanted or i.v. injected bone marrow stromal cells after inducing photochemical lesions in the cortex of the rat brain (144). Several research groups have tracked the migration of magnetically labelled

stem cells of different origin from the seeding site over corpus callosum to the damaged tissue in the contralateral hemisphere in rat brain with induced stroke (118, 122, 145). The tropism of labelled neural progenitor cells to gliomas has also been evaluated by cellular MRI (120), and tumour angiogenesis and neovasculature has been directly identified by tracking the labelled endothelial precursor cells in glioma models (115, 146). Also, Jiang and colleagues showed that neural progenitor cell induced angiogenesis after embolic stroke in the rat brain (147).

Imaging of endogenous cells requires *in vivo* labelling of cells with contrast agents. Shapiro and co-workers tracked the migratory pathway of endogenous neural precursor cells in the rat brain by direct injection of MPIOs in the lateral ventricles near the subventricular zone (148). Visualisation of damaged and regenerating optic nerves has been achieved by *in vivo* labelling with manganese following intraocular injection of the contrast agent (149).

#### ***1.7.4 Clinical implications of cellular MRI***

Direct imaging of pathological changes at the cellular/molecular level may provide a better detection of the disease which may have an impact on treatment strategies and patient care (111). So far, cellular MRI has mainly been used in experimental settings, but some clinical trials have been conducted. de Vries and co-workers demonstrated the potential of using cellular MRI for tracking therapeutic cells in melanoma patients as they were able to detect Endorem-labelled T-cells in lymph nodes (150). Zhu et al. were able to track Feridex-labelled NSC in a patient with brain trauma (151). However, an essential prerequisite of cellular MRI of patients is that cellular tracking can not interfere with the routine assessment of the disease. It is envisioned that cellular MRI will be a valuable tool for evaluating the efficacy of cell-based therapy strategies in the future (113).



## 2.0 Aims of the thesis

Based on the introduction, it is clear that there is still a lack of knowledge in understanding the progression and biological behaviour of glioma growth, as well as their response to new treatment modalities. Therefore, the main aim of this thesis was to investigate brain tumour phenotypes and brain tumour therapy strategies in animal models using forefront MR imaging techniques, novel contrast agents and advanced data analysis strategies.

**Paper I:** To investigate brain tumour characteristics using multiparametric MR imaging and subsequent multiparametric data analyses to identify NG2 as a mediator of aggressive tumour cell behaviour *in vivo*.

**Paper II:** To evaluate the potential of GRID for cell tracking with cellular MRI by investigating its relaxivity and its effects on labelled NSCs *in vitro*.

**Paper III:** To investigate the potential of NSCs as a vehicle for targeted therapy of brain tumours using a rat glioma model and *in vivo* cellular multiparametric MRI.

### **3.0 Discussion**

In this thesis, a broad range of MR imaging techniques has been applied to assess tumour progression longitudinally and to evaluate cell-based treatment strategies. *In vivo* MR findings have been corroborating *ex vivo* histological data, which is regarded as the method of choice when evaluating tumour aggressiveness and tumour grading. MRI proved to be a valuable tool for achieving both structural and functional information and provided important information about the biological status of the gliomas. Also, we were able to track the migration of magnetically labelled NSCs from the seeding site to the glioma region.

### **3.1 Experimental design**

#### ***3.1.1 Experimental glioma models***

In paper I, the U251 human glioma cell line was used. This cell line was initiated from a biopsy taken from a 57 year old male patient diagnosed with GBM (152). To avoid rejection of the grafted cells, human derived cell lines are usually xenotransplanted into immunocompromised mice or rats. The U251 tumour are pleomorphic, induce angiogenesis, necrosis, and show progressive growth when injected into congenitally athymic animals (152). This cell line was genetically modified to express NG2 (U251-NG2) (64). Xenografted U251-NG2 cells give rise to more vascularised, structurally distinct lesions *in vivo* (64). This model is therefore well suited to investigate whether the vasculature of NG2 positive tumours was structurally and functionally distinct from the NG2 negative tumour vasculature.

In paper II and III, the CNS-1 rat glioma cell line was used in both *in vitro* and *in vivo* assessments of the migratory potential of GRID-labelled NSCs. The CNS-1 astrocytoma is a chemically induced tumour derived from an inbred Lewis rat that had received i.v. injection of N-nitroso-N-methylurea (NNU) weekly during a period of six months (153). The CNS-1 tumour has been characterised as an astrocytoma based on its immunoreactivity for glial fibrillary acidic protein (GFAP) and S100 protein. When implanted intracranially into rats, the histopathological characteristics of the CNS-1 tumours show many histopathological characteristics similar to those of human GBMs. CNS-1

tumours are highly angiogenic, show perivascular infiltration, and single cell migration into brain parenchyma (153, 154), as well as necrosis with palisading cells in the tumour centre (154). CNS-1 tumours also show extensive macrophage infiltration (155), as also seen in human GBMs (156). All these biological characteristics make CNS-1 tumours an attractive model for studying underlying mechanisms behind tumour progression, as well as novel treatment strategies. Also, since the CNS-1 tumours exhibited many of the same heterogeneous signal changes on MR images as detected in human GBMs, the model is well suited for evaluating the applicability of using GRID for cell tracking.

### ***3.1.2 Quantification of microvascular parameters***

Perfusion is central to our understanding of the tumour microenvironment, and DCE-MRI is one method that may provide this information. However, there are both biological and methodological issues that may complicate accurate measurements of microvessel permeability parameters. Tumour vasculature is highly disorganised, vessels are tortuous and dilated with uneven lumen diameters and the blood flow may be chaotic and dysfunctional. The vasculature in and around brain tumours exhibits a wide range of permeabilities, from normal capillaries with essential no BBB leakage to tumour vasculature that freely passes even large molecules. Thus, an important step towards measurements that are closely linked to the underlying pathophysiology is to choose appropriate data analysis methods.

The enhancement kinetics of a tumour seen on T1-weighted images are dependent on several factors, including tissue blood flow, capillary permeability to the contrast agent, volume of extracellular space, inherent T1 relaxation time of the tissue, type and dose of contrast agent used, as well as imaging sequence and parameters (157). Another important issue is the potential occurrence and degree of spatial misregistration between image frames in the dynamic imaging time series. To reduce a potential bias, the animals were carefully immobilised. Thereafter post acquisition image co-registration and realignment were performed (using corresponding control points with a normalised cross-correlation technique, followed by conformal transformation from pairs of control points). The resulting cine loops of dynamic images were then inspected visually.

Objective analyses of microvascular parameters can be performed by semiquantitative analysis (measuring changes in signal intensity) or by fitting pharmacokinetic models to tissue contrast agent concentration-time curves (converting signal intensities to tissue concentrations). Semiquantitative parameters are relatively straightforward to calculate but an important limitation is that they do not accurately reflect the contrast agent concentration, are strongly dependent on acquisition parameters, and may not be physiologically based (157).

Paper I was aimed at describing the functional status of vessels in tumours by quantifying microvascular parameters using two different pharmacokinetic models developed by Su and co-workers (19, 158, 159) and Tofts and colleagues (89, 90, 160). The signal intensity curve was converted to tissue concentration based on the assumption that the increase in T1 relaxation rate is proportional to the concentration of the tracer:

$$C_T = [1/T_{1c} - 1/T_{10}] \cdot 1/r_1,$$

where  $C_T$  is the tissue concentration of the tracer in the tissue,  $T_{1c}$  is the relaxation time at a given tracer concentration,  $T_{10}$  is the relaxation time in the absence of the tracer, and  $r_1$  is the contrast agent's T1-relaxivity. Both models are also based on the following biological assumptions: i) the tracer is well mixed in the plasma, ii) there are two compartments available for the tracer; blood plasma and extravascular extracellular space (EES), and iii) flow is larger than the depletion of the tracer due to leakage (i.e. permeability-limited models). Also, they assume that there is a bi-directional exchange between the vessels and EES, where  $D_1$  and  $K^{trans}$  describe vessel-tissue leakage and  $K_2$  and  $k_{ep}$  the tracer's wash-out rate or rate constant from EES to blood (90, 158).

Su's model assumes that there is a slow to intermediate water exchange between the vascular and extravascular compartments. Therefore, the intra- and extravascular spaces relax with separate time constants. This allows an estimation of the fractional blood volume,  $D_0$ , which is related to the initial slope of the concentration-time curve (158). There may be some concerns regarding the validity of the analysis. First, quick leakage of the contrast agent into the extravascular space will lead to an over-estimation of the vascular space. Second, the assumption of slow water exchange is not always correct. In the case of a disrupted BBB, the transcapillary water exchange between intravascular and extravascular spaces increases (161). With an i.v. bolus injection, the longitudinal relaxation rate of water

---

protons in blood immediately increases and may also initially elevate the  $R_1$  in tissue. Tofts' model assumes fast water exchange between the intravascular and extravascular compartments. This results in a uniform  $T_1$  relaxation in the tissue as the tissue relaxes mono-exponentially with a relaxation rate given by the volume-weighted average of the compartment's relaxation rates. Thus, the total tissue concentration is estimated and the contribution of the intravascular tracer is neglected. However, in some cases such as brain tumours with increased blood volume, the intravascular tracer could contribute to a large portion of the observed tissue signal and give errors in the estimates of  $K^{\text{trans}}$  (90).

Based on these issues, we implemented both models to see whether our findings were mainly model dependent or if they could reflect genuine biological processes. When evaluating the suitability of the models on our data, pixel-wise numerical "goodness-of-fit" for the two pharmacokinetic models in different ROIs revealed that both models were well fitted to the time-concentration curves. However, Su's models showed a better fit at higher contrast agent concentrations, indicating that this model may be better in some cases (162). Since there was a good correlation between the permeability parameters obtained with the different pharmacokinetic models employed (i.e.  $D_1$  versus  $K^{\text{trans}}$ , and  $K_2$  versus  $k_{\text{ep}}$ , (162)), we were able to confirm that our findings are based on the biological differences between the two glioma phenotypes. Also, estimates of the fractional blood volumes based on MRI data were in concordance with estimates of MVD based on histological data. However, as we presented our data as mean values of the total tumour region, the heterogeneity of microvascular permeability may be masked. Tumour heterogeneity may be better visualised when presenting data as the distribution of the microvascular parameters in histograms and as voxel-wise parametric maps.

### ***3.1.3 Multiparametric imaging and data analyses***

Discrimination of the boundaries between malignant and normal tissue, and the evaluation of cellular heterogeneity in lesions, has proven to be a limitation in conventional MRI. The use of multiparametric or multispectral imaging and subsequent post image acquisition processing techniques, such as multiparametric data analysis, may provide more accurate information and hence, better tumour lesion characteristics. Multiparametric data analysis refers to simultaneous image analysis of multiple images that provide complementary information about the same scene (163, 164). After co-registration of the images as

described in section 3.1.2, we generated colour-coded images (RGB) from T2- (red channel), FLAIR (green channel), and T1-weighted post-contrast (blue channel) images based on the signal intensities (paper I). Each of the imaging sequences produced different tissue contrast. Classification and estimation of tumour lesion subvolumes such as peritumoural oedema, solid tumour tissue, and necrosis was performed by manual delineation on RGB images. Three-dimensional scatter plots or feature maps derived from the multiparametric images, displayed the simultaneous combination of the observed signal intensities, and were used as a visual control for the classification of the different subvolumes. However, the manual part of this procedure may induce interobserver or intraobserver variability, and automated methods such as segmentation based on global or local thresholding, or seed growing methods may be preferable (165).

In our multiparametric analysis of structural images we used three inputs (paper I), based on the assumption that separation of different tumour subvolumes will be improved using multiple imaging sequences. Because many tissues have overlapping MR signal intensities in a given channel, the use of three input images will increase the discrimination ability of different tumour subcompartments (165, 166).

When comparing contrast enhancement patterns of differently sized contrast agents (paper I), two input channels were used. Regions within the tumour with signal enhancement with Gadomer (green channel) and/or Gd-DTPA-BMA (red channel) were compared to visualise the differences in vessel permeability of high- and low-molecular weight tracers, respectively. A potential over- or under-estimation of the areas with signal enhancement after Gadomer injection is possible due to partial volume effects induced by poor spatial resolution of the DCE-MRI sequence. However, as differences in signal enhancement patterns between the two contrast agents were striking, the multiparametric voxel-wise maps may demonstrate important underlying biological mechanisms.

Multiparametric imaging also proved to be an important tool when evaluating tumour progression and cell migration of magnetically labelled stem cells in paper III. The contrast-to-noise ratio (CNR) was estimated in specific ROIs in different imaging sequences (i.e. T2-, T2\*-, and T1-weighted pre-contrast images) to visualise and quantify signal changes caused by the labelled stem cells in specific areas. Albeit we did not perform multiparametric analysis in terms of generating multiparametric maps, we were able to combine the

---

information obtained from the different imaging sequences, and demonstrate that changes in CNR on the images were most likely due the migration and homing of magnetically labelled cells into tumour tissue. Multiparametric imaging and subsequent CNR measurements also revealed signal changes due to migration of labelled cells that were not easily detected by the human eye.

### **3.1.4 Contrast agents**

Due to their versatile properties, Gd-based contrast agents were used in all three studies. Post-contrast T1-weighted images after i.v. injections of Gd-DTPA-BMA (molecular weight = 0.58 kDa) were employed for tumour detection, delineation of the solid tumour, and estimation of tumour volumes in paper I and III. While low-molecular weight Gd-based contrast agents are effective in distinguishing defective and leaky tumour endothelium from the normal counterparts, they only marginally discriminate the vasculature of distinct tumour types (159). Gadomer was therefore used as a tracer in DCE-MRI for evaluation of the microvascular permeability in tumours (paper I). This contrast agent is a dendritic gadolinium chelate containing 24 Gd-ions with a molecular weight of 17 kDa but because of its globular configuration, it has an apparent molecular weight of 30-35 kDa (167). Microvascular permeability assays using macromolecular contrast agents correlates well with histologic tumour grade (18), and seem to better reveal variations in tumour permeability than contrast agents with lower molecular weight (19, 168). Our results (paper I) support that notion. Earlier detection of changes in microvascular parameters after treatment have also been reported using macromolecular contrast agents (19, 20, 169). Moreover, high-molecular weight tracers as Gadomer may be more suitable for assessment of microvascular parameters using permeability-limited, pharmacokinetic models since their transport across the tumour vessels is slower than with low-molecular weight Gd-based contrast agents (170).

Cells were labelled with the bimodal contrast agent GRID to detect grafted NSCs in the rat brain (paper III). As Gd-based contrast agents have an effect on both T1 and T2 relaxation rates, signal changes in both T1-weighted and T2-weighted images could be expected. This may be of advantage when evaluating homing of labelled cells in tumour regions with very heterogeneous MR signals. However, previous *in vivo* studies using GRID reported signal attenuation on T2-weighted images but no signal enhancement on T1-

weighted images (122). This coincided with the *in vitro* signal intensity measurements in paper II. Despite relatively high T1 relaxivity of GRID at 4.7 T, no signal changes were detected in gels with labelled cells. This may be the result of sequestration, possible steric changes, and other impediments to water access and favourable motion characteristics of the contrast agent in the intracellular environment (126). However, the effect of intracellular GRID on T1-weighted images may evolve over time as higher concentrations of Gd inside the cells may quench the observed relaxivity (171). Despite being conditionally immortalised, the murine neural stem cells MHP36 may undergo 2-3 cell divisions before ceasing to proliferate in non-permissive conditions. This will result in a lower intracellular Gd-concentration over time before stabilising. Although it has been previously demonstrated that GRID does not leak from viable cells (119), the death of cells can result in GRID being present in the extracellular environment. It is therefore possible that signal increase on T1-weighted images was partly due to GRID that has been released by the death of some NSCs. Although cells labelled with GRID were detected by multiparametric imaging, it would be beneficial if the effects on image contrast on T1-weighted images were more pronounced, especially in pathological processes that exhibit a heterogeneous appearance on MR images. It is therefore desirable to identify an agent that will exert a strong T1 effect intracellularly as well as a T2 effect, allowing detection of cells in disease models in which the cells need to be conspicuous versus the tissue, and where cell numbers of interest may be low.

## **3.2 Experimental findings**

### ***3.2.1 NG2 expression mediates an aggressive glioma phenotype***

In paper I, the effects of NG2 on tumour progression were investigated. The tumours were longitudinally monitored *in vivo* using multiparametric MRI to assess vascular permeability, solid tumour volumes, vasogenic oedema and necrosis. This was done to determine whether NG2 expressing tumours showed different growth characteristics compared to its U251-WT (WT) wild type counterparts. The microvasculature of U251-NG2 tumours exhibited increased vessel leakiness expressed by higher  $D_1$ - and  $K^{\text{trans}}$  - values compared to WT tumours. Also, estimates of  $D_0$  as a measure of fractional blood volume revealed that NG2 expressing tumours had a larger blood supply than WT tumours. Immunohistochemistry and



---

electron-microscopy showed that the U251-NG2 tumours had a higher microvascular density (MVD) with vessels that displayed larger gaps between endothelial cells. Thus, tumour cells can regulate both the function and structure of the host derived tumour vasculature through NG2 expression, suggesting a role of NG2 in the cross-talk between tumour-host compartments.

NG2 expressing tumours also exhibited different features compared to WT tumours regarding tumour growth, vasogenic oedema and necrosis. U251-NG2 tumours rapidly developed with an accelerated expansion of the solid tumour mass, reflected by a shorter tumour volume doubling time than WT tumours. Development of MR visible necrotic foci correlated well with shorter survival of the U251-NG2 animals compared to the WT recipients. Our results showed that U251-NG2 tumour bearing animals developed vasogenic oedema in the surrounding brain parenchyma to a larger extent than WT animals, indicating that NG2 may play a role in the disruption of the BBB. This is an important finding as mechanisms of oedema formation in brain tumours are linked to tumourigenesis, and peritumoural oedema is a significant source of morbidity and mortality (172).

### ***3.2.2 Signal enhancement with differently sized contrast agents***

Qualitative analysis of the contrast enhancement pattern using different contrast agents revealed spatial heterogeneity in uptake depending on their molecular size (paper I). There is a spatial heterogeneity in blood supply of the solid tumour mass. Coupled with increased interstitial pressure centrally in the tumour, which lowers the extravasation of fluid and blood-borne molecules especially for macromolecular substances (173), it may explain the different contrast enhancement pattern between Gd-DTPA-BMA and Gadomer in these regions. Contrast enhancement with Gd-DTPA-BMA revealed a more homogeneous pattern, most likely due to a more rapid diffusion of smaller particles from the well-perfused peripheral region towards low-perfused central regions. These differences in the spatial tissue distribution of Gd-DTPA-BMA and Gadomer may indicate distinctive roles of the contrast agent in characterisation and estimation of tumour microvascular function. Treatment strategies based on blood-borne molecules are dependent on microvascular perfusion, permeability, and finally, the diffusion of the substance through the interstitium (174). Knowledge about spatial distribution of macromolecular particles is important for treatment planning and for the prediction of treatment response to blood-borne therapeutic

agents. The pattern of contrast enhancement in solid tumour tissue after administration of Gadomer may indicate the spatial distribution of therapeutic agents, and if so, it can be a valuable tool in treatment planning of blood-borne substances. Our results also indicate that Gd-DTPA-BMA, most likely due to higher permeability and faster diffusion, is better for the delineation and visualisation of viable tumour tissue. Qualitative analysis of contrast enhancement pattern also revealed pronounced differences in the uptake of different contrast agents in the WT compared to the U251-NG2 tumours. This may be explained by a lower permeability of large molecules in less aggressive tumours.

### **3.2.3 GRID visualises cells both *in vitro*, *in vivo* and *ex vivo***

The bimodal properties of GRID both allowed visualisation of labelled cells with fluorescence microscopy and MRI, as well as investigations of the migratory potential of labelled NSCs *in vivo* and *ex vivo* (paper III). *In vitro* identification of GRID-labelled cells in gels was also possible with MRI (paper II). The cells were fully saturated with GRID (100% labelling efficacy) after 16 hours of incubation as detected with both relative fluorescence measurements and ICP-MS. This is important when evaluating the fate and potential effects of the grafted labelled cells *in vivo* as the unlabelled fraction of cells will not induce signal changes and can therefore not be detected by cellular MRI. A minimum incubation time is desirable, and we found that 16 hours of incubation is acceptable. In comparison, cell labelling with the iron-oxide based contrast agent Endorem required up to 72 hours of incubation to obtain sufficient uptake of the contrast agent (144). Fluorescent micrographs demonstrated that intracellular GRID was located in the cytoplasm of MHP36 cells, and that cells could be detected up to one week after labelling in both permissive and non-permissive conditions (paper II). *In vivo* experiments showed that signal changes induced by labelled cells were detected by MRI 9 days after grafting, indicating good cellular preservation of the contrast agent (paper III). These results are consistent with previous findings (122, 129). GRID-labelled cells induced signal attenuation on T2-weighted images and a modest signal enhancement on T1-weighted images, which were quantified by CNR measurements (paper III).

---

#### **3.2.4 GRID does not impair cellular functions of labelled cells *in vitro***

Attractive properties of NSCs in stem cell-based therapies are their potential to generate a more differentiated progeny, capacity of self-renewal, and their motility as a response to pathological cues. These issues were addressed in paper II. MHP36 cells showed preserved differentiation after labelling with GRID as these cells developed into oligodendrocytes, astrocytes and neurons under appropriate conditions. Compared to PKH26 labelled NSCs, the migratory potential of GRID-labelled NSCs were not affected, indicating that labelled cells keep their ability to respond to pathological processes.

The toxicity of GRID was also investigated in terms of viability, proliferation, and metabolism. A significantly increased level of reactive oxygen species was seen in labelled cells but this was not reflected in a decrease in viability. However, proliferation of GRID-labelled NSCs dependent on the length of incubation, and cell counting revealed significant decrease in proliferation after 16 and 24 hours of labelling. Confirming these results, a 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT) assay, showed a reduction of mitochondrial activity after 24 hours of labelling. Decreased MTT ratio of labelled cells with Gd-based agents compared with unlabelled cells has also been observed by others (126). Decreased proliferation/metabolism in cells after labelling of Gd-based agents may be due to possible interactions of released Gd-ions with calcium channels and an interference with electron transport and mitochondrial function (175). However, high viability of labelled cells indicates that Gd-ions are not released in cells, and that the reduced mitochondrial activity is induced by other properties of GRID. The biological impact of the reduction in mitochondrial activity may not be of biological significance as cellular functions of labelled cells were not impaired. Based on this, GRID may be regarded as a safe and reliable method for labelling cells in animal models. However, potential long-term toxicity and the *in vivo* cellular effects of GRID and other Gd-based contrast agents should be thoroughly investigated before employing this contrast agent as a cellular tracer in humans.

#### **3.2.5 NSCs as a therapeutic modality in brain tumours**

GRID-labelled NSCs exhibited transhemispheric migration from the seeding site to the tumour regions in rat brains as demonstrated both with *in vivo* serial cellular MRI and with

*ex vivo* histological assessments (paper III). This confirms previous observations showing that NSCs are attracted by signals derived from the tumour (47, 55). NSCs respond to three physiological processes that are common to many brain pathologies: inflammation, reactive astrogliosis and angiogenesis (53). A potential intrinsic tumour-inhibitory effect of grafted NSCs was observed, reflected by a decreased tumour doubling time and reduced vasogenic oedema in NSCs treated animals. The exact molecular mechanism for this intrinsic effect of NSCs is not known but our findings confirm previous reports (48, 59). Cytolytic viruses and genes coding for anti-tumor cytokines, pro-drug converting enzymes, and various neurotrophic factors have all been engineered into engraftable NSCs for targeted delivery to tumours (140). However, genetically modified, transplanted NSCs may persist in brain well after their therapeutic action and continued expression of therapeutic molecules may show negative effects on normal neighbouring tissues.

### **3.3 Concluding remarks**

The recognition of NG2 as a progenitor/stem cell marker (69, 176) and its role in tumour progression, illustrates the dual role of such immature cells in healthy and diseased CNS. This thesis integrated both the pathological and the therapeutic effects of such cells in gliomas.

Multiparametric MR imaging and data analyses revealed that the NG2 expressing tumours have an increased vascular permeability and blood fraction, more prominent vasogenic oedema and necrosis, as well as an accelerated tumour growth. Based on these findings, we postulate that NG2 expression mediates a more aggressive glioma phenotype. Its involvement in multiple facets of tumour cell biology, underlines its potential as a possible therapeutic target.

MRI proved to be an important tool in evaluating NSCs as a vehicle to target the tumour. Cellular MRI visualised the migration and homing of GRID-labelled NSC to brain tumours. The Gd-based bimodal contrast agent GRID proved to be an efficient method to label cells and allowed the detection of grafted cells by MRI both *in vitro* and *in vivo*. GRID did not change the biological behaviour of labelled cells *in vitro* underlining the attractive role of NSCs as therapeutic vehicles.

## 4.0 Future prospects

The potential use of NSCs in brain tumour therapy will most likely represent a supplementary treatment approach that should not substitute conventional treatment strategies (177). However, the unique ability of NSCs to "home in" on tumour cells followed by the delivery of a desired gene product makes NSCs a very promising agent in brain tumour therapy. An interesting strategy is to use genetically engineered NSCs to target BTSCs which are believed to initiate tumourigenesis and maintain tumour growth. Normal stem cells share many properties with cancer stem cells, most notably the trait of self-renewal, and the question whether BTSCs are diseased NSCs has been raised (178, 179). Thus, it will be imperative to secure that grafted cells can not be transformed into tumour-initiating cells. Most stem cell-based gene therapy concepts are still in the preclinical evaluation phase and will have to pass significant hurdles to become viable therapeutic options. In this context it is important to assess potential hazards and outline safety measures related to cell therapy approaches.

*In vivo* evaluation of the efficacy of stem cell-based therapy is possible using cellular MRI and further developments of contrast agents for cellular labelling and FDA-approval of these, will emphasise the role of cellular MRI. Functional MRI will most likely be an integrated part in monitoring tumour progression and treatment response. More extensive use of (semi)automated pattern recognition techniques for multispectral data analyses, where conventional images are combined or replaced with pharmacokinetic maps and/or ADC maps to generate multidimensional feature maps, will also provide valuable information.

## References

1. Nitz WR, Reimer P. Contrast mechanisms in MR imaging. *Eur Radiol* 1999;9(6):1032-1046.
2. Huettel SA, Song AW, McCarthy G. *Functional Magnetic Resonance Imaging*. First ed. Sunderland, Massachusetts, USA: Sinauer Associates Inc., 2004.
3. Rabi II, Zacharias JR, Millmann S, Kush P. A new method of measuring nuclear magnetic moments. *Phys Rev* 1938;53:318.
4. Purcell EU, Torrey HC, Pound RV. Resonance absorption by nuclear magnetic resonance in solids. *Phys Rev* 1946;69:37-38.
5. Bloch F. Nuclear Induction. *Phys Rev* 1946;70:460-474.
6. Bloch F, Hansen WW. Nuclear Induction. *Phys Rev* 1946;69:127.
7. Damadian R. Tumor detection by nuclear magnetic resonance. *Science* 1971;171(976):1151-1153.
8. Lauterbur PC. Image formation by induced local interactions: examples employing nuclear magnetic resonance. *Nature* 1973;242:190-191.
9. Haacke EM, Brown RW, Thompson MR, Venkatesan R. *Magnetic Resonance Imaging ~ Physical Principles and Sequence Design*. First ed: Wiley-Liss, 1999.
10. Brasch RC. Rationale and applications for macromolecular Gd-based contrast agents. *Magn Reson Med* 1991;22(2):282-287; discussion 300-283.
11. Donahue KM, Weisskoff RM, Burstein D. Water diffusion and exchange as they influence contrast enhancement. *J Magn Reson Imaging* 1997;7(1):102-110.
12. Barbier EL, den Boer JA, Peters AR, Rozeboom AR, Sau J, Bonmartin A. A model of the dual effect of gadopentetate dimeglumine on dynamic brain MR images. *J Magn Reson Imaging* 1999;10(3):242-253.
13. Weinmann HJ, Ebert W, Misselwitz B, Schmitt-Willich H. Tissue-specific MR contrast agents. *Eur J Radiol* 2003;46(1):33-44.
14. Bock JC, Henrikson O, Gotze AH, Wlodarczyk W, Sander B, Felix R. Magnetic resonance perfusion imaging with gadolinium-DTPA. A quantitative approach for the kinetic analysis of first-pass residue curves. *Invest Radiol* 1995;30(12):693-699.
15. Felix R, Heshiki A, Hosten N, Hricak H. Safety and risk of Gadolinium-GDTPA: Extended clinical experience after more than 20 million applications. In: *Magnevist monograph*. Berlin: Blackwell Wissenschafts-Verlag, 1998.
16. Essig M. MR imaging of CNS tumors: are all contrast agents created the same? *Neuroradiology* 2006;48 Suppl 1:3-8.

17. Taschner CA, Wetzel SG, Tolnay M, Froehlich J, Merlo A, Radue EW. Characteristics of ultrasmall superparamagnetic iron oxides in patients with brain tumors. *AJR Am J Roentgenol* 2005;185(6):1477-1486.
18. Daldrup H, Shames DM, Wendland M, Okuhata Y, Link TM, Rosenau W, et al. Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. *AJR Am J Roentgenol* 1998;171(4):941-949.
19. Su MY, Wang Z, Nalcioğlu O. Investigation of longitudinal vascular changes in control and chemotherapy-treated tumors to serve as therapeutic efficacy predictors. *J Magn Reson Imaging* 1999;9(1):128-137.
20. Kim YH, Choi BI, Cho WH, Lim S, Moon WK, Han JK, et al. Dynamic contrast-enhanced MR imaging of VX2 carcinomas after X-irradiation in rabbits: comparison of gadopentetate dimeglumine and a macromolecular contrast agent. *Invest Radiol* 2003;38(9):539-549.
21. Roberts TP, Turetschek K, Preda A, Novikov V, Moeglich M, Shames DM, et al. Tumor microvascular changes to anti-angiogenic treatment assessed by MR contrast media of different molecular weights. *Acad Radiol* 2002;9 Suppl 2:S511-513.
22. Goldberg SN. Science to practice: can we differentiate residual untreated tumor from tissue responses to heat following thermal tumor ablation? *Radiology* 2005;234(2):317-318.
23. Jung CW. Surface properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. *Magn Reson Imaging* 1995;13(5):675-691.
24. Enochs WS, Harsh G, Hochberg F, Weissleder R. Improved delineation of human brain tumors on MR images using a long-circulating, superparamagnetic iron oxide agent. *J Magn Reson Imaging* 1999;9(2):228-232.
25. Zimmer C, Weissleder R, Poss K, Bogdanova A, Wright SC, Jr., Enochs WS. MR imaging of phagocytosis in experimental gliomas. *Radiology* 1995;197(2):533-538.
26. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. *Acta Neuropathol (Berl)* 2005;109(1):93-108.
27. Lonn S, Klaeboe L, Hall P, Mathiesen T, Auvinen A, Christensen HC, et al. Incidence trends of adult primary intracerebral tumors in four Nordic countries. *Int J Cancer* 2004;108(3):450-455.
28. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, et al. The WHO classification of tumors of the nervous system. *J Neuropathol Exp Neurol* 2002;61(3):215-225; discussion 226-219.
29. Kleihues P, Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. *Neuro-oncol* 1999;1(1):44-51.

- 
30. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, et al. Genetic pathways to glioblastoma: a population-based study. *Cancer Res* 2004;64(19):6892-6899.
  31. Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell* 2000;100(1):57-70.
  32. Singh SK, Clarke ID, Hide T, Dirks PB. Cancer stem cells in nervous system tumors. *Oncogene* 2004;23(43):7267-7273.
  33. Clarke MF, Fuller M. Stem cells and cancer: two faces of eve. *Cell* 2006;124(6):1111-1115.
  34. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, et al. Identification of a cancer stem cell in human brain tumors. *Cancer Res* 2003;63(18):5821-5828.
  35. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. *Nature* 2004;432(7015):396-401.
  36. Schulenburg A, Ulrich-Pur H, Thurnher D, Erovic B, Florian S, Sperr WR, et al. Neoplastic stem cells: a novel therapeutic target in clinical oncology. *Cancer* 2006;107(10):2512-2520.
  37. Pilkington GJ. Tumour cell migration in the central nervous system. *Brain Pathol* 1994;4(2):157-166.
  38. Berens ME, Giese A. "...those left behind." Biology and oncology of invasive glioma cells. *Neoplasia* 1999;1(3):208-219.
  39. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. *Nature* 2000;407(6801):249-257.
  40. Folkman J, Beckner K. Angiogenesis imaging. *Acad Radiol* 2000;7(10):783-785.
  41. Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, et al. Openings between defective endothelial cells explain tumor vessel leakiness. *Am J Pathol* 2000;156(4):1363-1380.
  42. Burton EC, Prados MD. Malignant gliomas. *Curr Treat Options Oncol* 2000;1(5):459-468.
  43. Rainov NG, Soling A, Heidecke V. Novel therapies for malignant gliomas: a local affair? *Neurosurg Focus* 2006;20(4):E9.
  44. Chamberlain MC. Treatment options for glioblastoma. *Neurosurg Focus* 2006;20(4):E2.
  45. Hou LC, Veeravagu A, Hsu AR, Tse VC. Recurrent glioblastoma multiforme: a review of natural history and management options. *Neurosurg Focus* 2006;20(4):E5.
  46. Recht L, Jang T, Savarese T, Litofsky NS. Neural stem cells and neuro-oncology: quo vadis? *J Cell Biochem* 2003;88(1):11-19.



- 
47. Aboody KS, Brown A, Rainov NG, Bower KA, Liu S, Yang W, et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. *Proc Natl Acad Sci U S A* 2000;97(23):12846-12851.
  48. Benedetti S, Pirola B, Pollo B, Magrassi L, Bruzzone MG, Rigamonti D, et al. Gene therapy of experimental brain tumors using neural progenitor cells. *Nat Med* 2000;6(4):447-450.
  49. Ehtesham M, Kabos P, Gutierrez MA, Chung NH, Griffith TS, Black KL, et al. Induction of glioblastoma apoptosis using neural stem cell-mediated delivery of tumor necrosis factor-related apoptosis-inducing ligand. *Cancer Res* 2002;62(24):7170-7174.
  50. Herrlinger U, Woiciechowski C, Sena-Esteves M, Aboody KS, Jacobs AH, Rainov NG, et al. Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas. *Mol Ther* 2000;1(4):347-357.
  51. Noble M. Can neural stem cells be used to track down and destroy migratory brain tumor cells while also providing a means of repairing tumor-associated damage? *Proc Natl Acad Sci U S A* 2000;97(23):12393-12395.
  52. Noble M, Dietrich J. Intersections between neurobiology and oncology: tumor origin, treatment and repair of treatment-associated damage. *Trends Neurosci* 2002;25(2):103-107.
  53. Muller FJ, Snyder EY, Loring JF. Gene therapy: can neural stem cells deliver? *Nat Rev Neurosci* 2006;7(1):75-84.
  54. Barresi V, Belluardo N, Sipione S, Mudo G, Cattaneo E, Condorelli DF. Transplantation of prodrug-converting neural progenitor cells for brain tumor therapy. *Cancer Gene Ther* 2003;10(5):396-402.
  55. Schmidt NO, Przylecki W, Yang W, Ziu M, Teng Y, Kim SU, et al. Brain tumor tropism of transplanted human neural stem cells is induced by vascular endothelial growth factor. *Neoplasia* 2005;7(6):623-629.
  56. Shah K, Bureau E, Kim DE, Yang K, Tang Y, Weissleder R, et al. Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression. *Ann Neurol* 2005;57(1):34-41.
  57. Ehtesham M, Kabos P, Kabosova A, Neuman T, Black KL, Yu JS. The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma. *Cancer Res* 2002;62(20):5657-5663.
  58. Lee J, Elkahlon AG, Messina SA, Ferrari N, Xi D, Smith CL, et al. Cellular and genetic characterization of human adult bone marrow-derived neural stem-like cells: a potential antiglioma cellular vector. *Cancer Res* 2003;63(24):8877-8889.
  59. Staffin K, Honeth G, Kalliomaki S, Kjellman C, Edvardsen K, Lindvall M. Neural progenitor cell lines inhibit rat tumor growth in vivo. *Cancer Res* 2004;64(15):5347-5354.

- 
60. Thallmair M, Ray J, Stallcup WB, Gage FH. Functional and morphological effects of NG2 proteoglycan deletion on hippocampal neurogenesis. *Exp Neurol* 2006;202(1):167-178.
  61. Levine JM, Beasley L, Stallcup WB. Localization of a neurectoderm-associated cell surface antigen in the developing and adult rat. *Brain Res* 1986;392(1-2):211-222.
  62. Chekenya M, Rooprai HK, Davies D, Levine JM, Butt AM, Pilkington GJ. The NG2 chondroitin sulfate proteoglycan: role in malignant progression of human brain tumours. *Int J Dev Neurosci* 1999;17(5-6):421-435.
  63. Chekenya M, Enger PO, Thorsen F, Tysnes BB, Al-Sarraj S, Read TA, et al. The glial precursor proteoglycan, NG2, is expressed on tumour neovasculature by vascular pericytes in human malignant brain tumours. *Neuropathol Appl Neurobiol* 2002;28(5):367-380.
  64. Chekenya M, Hjelstuen M, Enger PO, Thorsen F, Jacob AL, Probst B, et al. NG2 proteoglycan promotes angiogenesis-dependent tumor growth in CNS by sequestering angiostatin. *Faseb J* 2002;16(6):586-588.
  65. Goretzki L, Lombardo CR, Stallcup WB. Binding of the NG2 proteoglycan to kringle domains modulates the functional properties of angiostatin and plasmin(ogen). *J Biol Chem* 2000;275(37):28625-28633.
  66. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. *Cancer Cell* 2004;6(6):553-563.
  67. Chekenya M, Pilkington GJ. NG2 precursor cells in neoplasia: functional, histogenesis and therapeutic implications for malignant brain tumours. *J Neurocytol* 2002;31(6-7):507-521.
  68. Chekenya M, Immervoll H. NG2/HMP Proteoglycan as a Cancer Therapeutic Target. In: Sioud M, ed. *Target discovery and validation reviews and protocols - Emerging molecular targets and treatment options*. Totowa, New Jersey: Humana Press, 2007: 93-118.
  69. Shoshan Y, Nishiyama A, Chang A, Mork S, Barnett GH, Cowell JK, et al. Expression of oligodendrocyte progenitor cell antigens by gliomas: implications for the histogenesis of brain tumors. *Proc Natl Acad Sci U S A* 1999;96(18):10361-10366.
  70. Barth RF. Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. *J Neurooncol* 1998;36(1):91-102.
  71. Holland EC. Brain tumor animal models: importance and progress. *Curr Opin Oncol* 2001;13(3):143-147.
  72. Bjerkvig R, Tonnesen A, Laerum OD, Backlund EO. Multicellular tumor spheroids from human gliomas maintained in organ culture. *J Neurosurg* 1990;72(3):463-475.

- 
73. Sakariassen PO, Prestegarden L, Wang J, Skaftnesmo KO, Mahesparan R, Molthoff C, et al. Angiogenesis-independent tumor growth mediated by stem-like cancer cells. *Proc Natl Acad Sci U S A* 2006;103(44):16466-16471.
  74. Henson JW, Gaviani P, Gonzalez RG. MRI in treatment of adult gliomas. *Lancet Oncol* 2005;6(3):167-175.
  75. Jacobs AH, Kracht LW, Gossmann A, Ruger MA, Thomas AV, Thiel A, et al. Imaging in neurooncology. *NeuroRx* 2005;2(2):333-347.
  76. Sartor K. MR imaging of the brain: tumors. *Eur Radiol* 1999;9(6):1047-1054.
  77. Hammoud MA, Sawaya R, Shi W, Thall PF, Leeds NE. Prognostic significance of preoperative MRI scans in glioblastoma multiforme. *J Neurooncol* 1996;27(1):65-73.
  78. Husstedt HW, Sickert M, Kostler H, Haubitz B, Becker H. Diagnostic value of the fast-FLAIR sequence in MR imaging of intracranial tumors. *Eur Radiol* 2000;10(5):745-752.
  79. Hajnal JV, Bryant DJ, Kasuboski L, Pattany PM, De Coene B, Lewis PD, et al. Use of fluid attenuated inversion recovery (FLAIR) pulse sequences in MRI of the brain. *J Comput Assist Tomogr* 1992;16(6):841-844.
  80. Kubota T, Yamada K, Kizu O, Hirota T, Ito H, Ishihara K, et al. Relationship between contrast enhancement on fluid-attenuated inversion recovery MR sequences and signal intensity on T2-weighted MR images: visual evaluation of brain tumors. *J Magn Reson Imaging* 2005;21(6):694-700.
  81. Essig M, Knopp MV, Schoenberg SO, Hawighorst H, Wenz F, Debus J, et al. Cerebral gliomas and metastases: assessment with contrast-enhanced fast fluid-attenuated inversion-recovery MR imaging. *Radiology* 1999;210(2):551-557.
  82. Cao Y, Sundgren PC, Tsien CI, Chenevert TT, Junck L. Physiologic and metabolic magnetic resonance imaging in gliomas. *J Clin Oncol* 2006;24(8):1228-1235.
  83. Padhani AR. MRI for assessing antivasular cancer treatments. *Br J Radiol* 2003;76 Spec No 1:S60-80.
  84. Preda A, van Vliet M, Krestin GP, Brasch RC, van Dijke CF. Magnetic resonance macromolecular agents for monitoring tumor microvessels and angiogenesis inhibition. *Invest Radiol* 2006;41(3):325-331.
  85. Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, et al. Assessment of antiangiogenic and antivasular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. *Br J Radiol* 2003;76 Spec No 1:S87-91.
  86. Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, et al. The assessment of antiangiogenic and antivasular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. *Br J Cancer* 2005;92(9):1599-1610.

- 
87. Brix G, Semmler W, Port R, Schad LR, Layer G, Lorenz WJ. Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. *J Comput Assist Tomogr* 1991;15(4):621-628.
  88. Larsson HB, Stubgaard M, Frederiksen JL, Jensen M, Henriksen O, Paulson OB. Quantitation of blood-brain barrier defect by magnetic resonance imaging and gadolinium-DTPA in patients with multiple sclerosis and brain tumors. *Magn Reson Med* 1990;16(1):117-131.
  89. Tofts PS, Kermode AG. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. *Magn Reson Med* 1991;17(2):357-367.
  90. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. *J Magn Reson Imaging* 1999;10(3):223-232.
  91. Roberts HC, Roberts TP, Brasch RC, Dillon WP. Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. *AJNR Am J Neuroradiol* 2000;21(5):891-899.
  92. Mills SJ, Patankar TA, Haroon HA, Baleriaux D, Swindell R, Jackson A. Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma? *AJNR Am J Neuroradiol* 2006;27(4):853-858.
  93. Ludemann L, Grieger W, Wurm R, Budzisch M, Hamm B, Zimmer C. Comparison of dynamic contrast-enhanced MRI with WHO tumor grading for gliomas. *Eur Radiol* 2001;11(7):1231-1241.
  94. Zhu XP, Li KL, Kamaly-Asl ID, Checkley DR, Tessier JJ, Waterton JC, et al. Quantification of endothelial permeability, leakage space, and blood volume in brain tumors using combined T1 and T2\* contrast-enhanced dynamic MR imaging. *J Magn Reson Imaging* 2000;11(6):575-585.
  95. Law M, Yang S, Babb JS, Knopp EA, Golfinos JG, Zagzag D, et al. Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. *AJNR Am J Neuroradiol* 2004;25(5):746-755.
  96. Cao Y, Shen Z, Chenevert TL, Ewing JR. Estimate of vascular permeability and cerebral blood volume using Gd-DTPA contrast enhancement and dynamic T2\*-weighted MRI. *J Magn Reson Imaging* 2006;24(2):288-296.
  97. Provenzale JM, Wang GR, Brenner T, Petrella JR, Sorensen AG. Comparison of permeability in high-grade and low-grade brain tumors using dynamic susceptibility contrast MR imaging. *AJR Am J Roentgenol* 2002;178(3):711-716.

- 
98. Aronen HJ, Gazit IE, Louis DN, Buchbinder BR, Pardo FS, Weisskoff RM, et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. *Radiology* 1994;191(1):41-51.
  99. Donahue KM, Krouwer HG, Rand SD, Pathak AP, Marszalkowski CS, Censky SC, et al. Utility of simultaneously acquired gradient-echo and spin-echo cerebral blood volume and morphology maps in brain tumor patients. *Magn Reson Med* 2000;43(6):845-853.
  100. Park SH, Chang KH, Song IC, Kim YJ, Kim SH, Han MH. Diffusion-weighted MRI in cystic or necrotic intracranial lesions. *Neuroradiology* 2000;42(10):716-721.
  101. Lai PH, Ho JT, Chen WL, Hsu SS, Wang JS, Pan HB, et al. Brain abscess and necrotic brain tumor: discrimination with proton MR spectroscopy and diffusion-weighted imaging. *AJNR Am J Neuroradiol* 2002;23(8):1369-1377.
  102. Kim YJ, Chang KH, Song IC, Kim HD, Seong SO, Kim YH, et al. Brain abscess and necrotic or cystic brain tumor: discrimination with signal intensity on diffusion-weighted MR imaging. *AJR Am J Roentgenol* 1998;171(6):1487-1490.
  103. Kono K, Inoue Y, Nakayama K, Shakudo M, Morino M, Ohata K, et al. The role of diffusion-weighted imaging in patients with brain tumors. *AJNR Am J Neuroradiol* 2001;22(6):1081-1088.
  104. Yamasaki F, Kurisu K, Satoh K, Arita K, Sugiyama K, Ohtaki M, et al. Apparent diffusion coefficient of human brain tumors at MR imaging. *Radiology* 2005;235(3):985-991.
  105. Sugahara T, Korogi Y, Kochi M, Ikushima I, Shigematu Y, Hirai T, et al. Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. *J Magn Reson Imaging* 1999;9(1):53-60.
  106. Sadeghi N, Camby I, Goldman S, Gabius HJ, Baleriaux D, Salmon I, et al. Effect of hydrophilic components of the extracellular matrix on quantifiable diffusion-weighted imaging of human gliomas: preliminary results of correlating apparent diffusion coefficient values and hyaluronan expression level. *AJR Am J Roentgenol* 2003;181(1):235-241.
  107. Sinha S, Bastin ME, Whittle IR, Wardlaw JM. Diffusion tensor MR imaging of high-grade cerebral gliomas. *AJNR Am J Neuroradiol* 2002;23(4):520-527.
  108. Muti M, Aprile I, Principi M, Italiani M, Guiducci A, Giulianelli G, et al. Study on the variations of the apparent diffusion coefficient in areas of solid tumor in high grade gliomas. *Magn Reson Imaging* 2002;20(9):635-641.
  109. Chenevert TL, McKeever PE, Ross BD. Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. *Clin Cancer Res* 1997;3(9):1457-1466.

- 
110. Chenevert TL, Stegman LD, Taylor JM, Robertson PL, Greenberg HS, Rehemtulla A, et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. *J Natl Cancer Inst* 2000;92(24):2029-2036.
  111. Weissleder R, Mahmood U. Molecular imaging. *Radiology* 2001;219(2):316-333.
  112. Bulte JW, Kraitchman DL. Iron oxide MR contrast agents for molecular and cellular imaging. *NMR Biomed* 2004;17(7):484-499.
  113. Modo M, Hoehn M, Bulte JW. Cellular MR imaging. *Mol Imaging* 2005;4(3):143-164.
  114. Ghosh P, Hawrylack N, Broadus J, Greenough WT, Lauterbur PC. NMR imaging of transplanted iron-oxide labelled cells in the brain. In: *Proceeding of the 9th ISMRM*; 1990, 1990: 1193.
  115. Anderson SA, Glod J, Arbab AS, Noel M, Ashari P, Fine HA, et al. Noninvasive MR imaging of magnetically labeled stem cells to directly identify neovasculature in a glioma model. *Blood* 2005;105(1):420-425.
  116. Bulte JW, Zhang S, van Gelderen P, Herynek V, Jordan EK, Duncan ID, et al. Neurotransplantation of magnetically labeled oligodendrocyte progenitors: magnetic resonance tracking of cell migration and myelination. *Proc Natl Acad Sci U S A* 1999;96(26):15256-15261.
  117. Bulte JW, Douglas T, Witwer B, Zhang SC, Strable E, Lewis BK, et al. Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells. *Nat Biotechnol* 2001;19(12):1141-1147.
  118. Hoehn M, Kustermann E, Blunk J, Wiedermann D, Trapp T, Wecker S, et al. Monitoring of implanted stem cell migration in vivo: a highly resolved in vivo magnetic resonance imaging investigation of experimental stroke in rat. *Proc Natl Acad Sci U S A* 2002;99(25):16267-16272.
  119. Modo M, Cash D, Mellodew K, Williams SC, Fraser SE, Meade TJ, et al. Tracking transplanted stem cell migration using bifunctional, contrast agent-enhanced, magnetic resonance imaging. *Neuroimage* 2002;17(2):803-811.
  120. Zhang Z, Jiang Q, Jiang F, Ding G, Zhang R, Wang L, et al. In vivo magnetic resonance imaging tracks adult neural progenitor cell targeting of brain tumor. *Neuroimage* 2004;23(1):281-287.
  121. Shapiro EM, Skrtic S, Sharer K, Hill JM, Dunbar CE, Koretsky AP. MRI detection of single particles for cellular imaging. *Proc Natl Acad Sci U S A* 2004;101(30):10901-10906.
  122. Modo M, Mellodew K, Cash D, Fraser SE, Meade TJ, Price J, et al. Mapping transplanted stem cell migration after a stroke: a serial, in vivo magnetic resonance imaging study. *Neuroimage* 2004;21(1):311-317.

- 
123. Shapiro EM, Sharer K, Skrtic S, Koretsky AP. In vivo detection of single cells by MRI. *Magn Reson Med* 2006;55(2):242-249.
  124. Heyn C, Ronald JA, Ramadan SS, Snir JA, Barry AM, MacKenzie LT, et al. In vivo MRI of cancer cell fate at the single-cell level in a mouse model of breast cancer metastasis to the brain. *Magn Reson Med* 2006;56(5):1001-1010.
  125. Heyn C, Ronald JA, Mackenzie LT, MacDonald IC, Chambers AF, Rutt BK, et al. In vivo magnetic resonance imaging of single cells in mouse brain with optical validation. *Magn Reson Med* 2006;55(1):23-29.
  126. Anderson SA, Lee KK, Frank JA. Gadolinium-fullerenol as a paramagnetic contrast agent for cellular imaging. *Invest Radiol* 2006;41(3):332-338.
  127. Huber MM, Staubli AB, Kustedjo K, Gray MH, Shih J, Fraser SE, et al. Fluorescently detectable magnetic resonance imaging agents. *Bioconjug Chem* 1998;9(2):242-249.
  128. Daldrup-Link HE, Rudelius M, Metz S, Piontek G, Pichler B, Settles M, et al. Cell tracking with gadophrin-2: a bifunctional contrast agent for MR imaging, optical imaging, and fluorescence microscopy. *Eur J Nucl Med Mol Imaging* 2004;31(9):1312-1321.
  129. Modo M, Roberts TJ, Sandhu JK, Williams SC. In vivo monitoring of cellular transplants by magnetic resonance imaging and positron emission tomography. *Expert Opin Biol Ther* 2004;4(2):145-155.
  130. Himmelreich U, Aime S, Hieronymus T, Justicia C, Uggeri F, Zenke M, et al. A responsive MRI contrast agent to monitor functional cell status. *Neuroimage* 2006;32(3):1142-1149.
  131. Daldrup-Link HE, Rudelius M, Oostendorp RA, Settles M, Piontek G, Metz S, et al. Targeting of hematopoietic progenitor cells with MR contrast agents. *Radiology* 2003;228(3):760-767.
  132. Himmelreich U, Weber R, Ramos-Cabrer P, Wegener S, Kandal K, Shapiro EM, et al. Improved stem cell MR detectability in animal models by modification of the inhalation gas. *Mol Imaging* 2005;4(2):104-109.
  133. Aime S, Barge A, Cabella C, Crich SG, Gianolio E. Targeting cells with MR imaging probes based on paramagnetic Gd(III) chelates. *Curr Pharm Biotechnol* 2004;5(6):509-518.
  134. Bulte JW, Laughlin PG, Jordan EK, Tran VA, Vymazal J, Frank JA. Tagging of T cells with superparamagnetic iron oxide: uptake kinetics and relaxometry. *Acad Radiol* 1996;3 Suppl 2:S301-303.
  135. Arbab AS, Bashaw LA, Miller BR, Jordan EK, Bulte JW, Frank JA. Intracytoplasmic tagging of cells with ferumoxides and transfection agent for cellular magnetic resonance imaging after cell transplantation: methods and techniques. *Transplantation* 2003;76(7):1123-1130.

136. Kalish H, Arbab AS, Miller BR, Lewis BK, Zywicke HA, Bulte JW, et al. Combination of transfection agents and magnetic resonance contrast agents for cellular imaging: relationship between relaxivities, electrostatic forces, and chemical composition. *Magn Reson Med* 2003;50(2):275-282.
137. Wang YX, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. *Eur Radiol* 2001;11(11):2319-2331.
138. Goldman S. Stem and progenitor cell-based therapy of the human central nervous system. *Nat Biotechnol* 2005;23(7):862-871.
139. Boyle AJ, Schulman SP, Hare JM, Oettgen P. Is stem cell therapy ready for patients? Stem Cell Therapy for Cardiac Repair. Ready for the Next Step. *Circulation* 2006;114(4):339-352.
140. Yip S, Aboody KS, Burns M, Imitola J, Boockvar JA, Allport J, et al. Neural stem cell biology may be well suited for improving brain tumor therapies. *Cancer J* 2003;9(3):189-204.
141. Lindvall O, Kokaia Z, Martinez-Serrano A. Stem cell therapy for human neurodegenerative disorders-how to make it work. *Nat Med* 2004;10 Suppl:S42-50.
142. Anderson SA, Shukaliak-Quandt J, Jordan EK, Arbab AS, Martin R, McFarland H, et al. Magnetic resonance imaging of labeled T-cells in a mouse model of multiple sclerosis. *Ann Neurol* 2004;55(5):654-659.
143. Oweida AJ, Dunn EA, Foster PJ. Cellular imaging at 1.5 T: detecting cells in neuroinflammation using active labeling with superparamagnetic iron oxide. *Mol Imaging* 2004;3(2):85-95.
144. Jendelova P, Herynek V, DeCroos J, Glogarova K, Andersson B, Hajek M, et al. Imaging the fate of implanted bone marrow stromal cells labeled with superparamagnetic nanoparticles. *Magn Reson Med* 2003;50(4):767-776.
145. Zhang ZG, Jiang Q, Zhang R, Zhang L, Wang L, Arniago P, et al. Magnetic resonance imaging and neurosphere therapy of stroke in rat. *Ann Neurol* 2003;53(2):259-263.
146. Arbab AS, Pandit SD, Anderson SA, Yocum GT, Bur M, Frenkel V, et al. Magnetic resonance imaging and confocal microscopy studies of magnetically labeled endothelial progenitor cells trafficking to sites of tumor angiogenesis. *Stem Cells* 2006;24(3):671-678.
147. Jiang Q, Zhang ZG, Ding GL, Zhang L, Ewing JR, Wang L, et al. Investigation of neural progenitor cell induced angiogenesis after embolic stroke in rat using MRI. *Neuroimage* 2005;28(3):698-707.
148. Shapiro EM, Gonzalez-Perez O, Manuel Garcia-Verdugo J, Alvarez-Buylla A, Koretsky AP. Magnetic resonance imaging of the migration of neuronal precursors generated in the adult rodent brain. *Neuroimage* 2006;32(3):1150-1157.



- 
149. Thuen M, Singstad TE, Pedersen TB, Haraldseth O, Berry M, Sandvig A, et al. Manganese-enhanced MRI of the optic visual pathway and optic nerve injury in adult rats. *J Magn Reson Imaging* 2005;22(4):492-500.
  150. de Vries IJ, Lesterhuis WJ, Barentsz JO, Verdijk P, van Krieken JH, Boerman OC, et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. *Nat Biotechnol* 2005;23(11):1407-1413.
  151. Zhu J, Zhou L, XingWu F. Tracking neural stem cells in patients with brain trauma. *N Engl J Med* 2006;355(22):2376-2378.
  152. Bigner DD, Bigner SH, Ponten J, Westermark B, Mahaley MS, Ruoslahti E, et al. Heterogeneity of Genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas. *J Neuropathol Exp Neurol* 1981;40(3):201-229.
  153. Kruse CA, Molleston MC, Parks EP, Schiltz PM, Kleinschmidt-DeMasters BK, Hickey WF. A rat glioma model, CNS-1, with invasive characteristics similar to those of human gliomas: a comparison to 9L gliosarcoma. *J Neurooncol* 1994;22(3):191-200.
  154. Regina A, Demeule M, Berube A, Moundjian R, Berthelet F, Beliveau R. Differences in multidrug resistance phenotype and matrix metalloproteinases activity between endothelial cells from normal brain and glioma. *J Neurochem* 2003;84(2):316-324.
  155. Kielian T, van Rooijen N, Hickey WF. MCP-1 expression in CNS-1 astrocytoma cells: implications for macrophage infiltration into tumors in vivo. *J Neurooncol* 2002;56(1):1-12.
  156. Giometto B, Bozza F, Faresin F, Alessio L, Mingrino S, Tavolato B. Immune infiltrates and cytokines in gliomas. *Acta Neurochir (Wien)* 1996;138(1):50-56.
  157. Brasch RC, Li KC, Husband JE, Keogan MT, Neeman M, Padhani AR, et al. In vivo monitoring of tumor angiogenesis with MR imaging. *Acad Radiol* 2000;7(10):812-823.
  158. Su MY, Jao JC, Nalcioglu O. Measurement of vascular volume fraction and blood-tissue permeability constants with a pharmacokinetic model: studies in rat muscle tumors with dynamic Gd-DTPA enhanced MRI. *Magn Reson Med* 1994;32(6):714-724.
  159. Su MY, Muhler A, Lao X, Nalcioglu O. Tumor characterization with dynamic contrast-enhanced MRI using MR contrast agents of various molecular weights. *Magn Reson Med* 1998;39(2):259-269.
  160. Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. *J Magn Reson Imaging* 1997;7(1):91-101.
  161. Cao Y, Nagesh V, Hamstra D, Tsien CI, Ross BD, Chenevert TL, et al. The extent and severity of vascular leakage as evidence of tumor aggressiveness in high-grade gliomas. *Cancer Res* 2006;66(17):8912-8917.

- 
162. Stålsett E. In vivo mapping of tumour microcirculation parameters using dynamic contrast enhanced MR imaging [Cand. scient thesis]. Bergen: University of Bergen, 2004.
  163. Carano RA, Ross AL, Ross J, Williams SP, Koeppen H, Schwall RH, et al. Quantification of tumor tissue populations by multispectral analysis. *Magn Reson Med* 2004;51(3):542-551.
  164. Duda RO, Hart. PE, Stork DG. *Pattern Classification*. 2nd ed. New York: Wiley-Liss, 2001.
  165. Gordon J, Mohamed F, Vinitiski S, Knobler RL, Curtis M, Faro S, et al. Utilization of experimental animal model for correlative multispectral MRI and pathological analysis of brain tumors. *Magn Reson Imaging* 1999;17(10):1495-1502.
  166. Vinitiski S, Gonzalez C, Mohamed F, Iwanaga T, Knobler RL, Khalili K, et al. Improved intracranial lesion characterization by tissue segmentation based on a 3D feature map. *Magn Reson Med* 1997;37(3):457-469.
  167. Misselwitz B, Schmitt-Willich H, Ebert W, Frenzel T, Weinmann HJ. Pharmacokinetics of Gadomer-17, a new dendritic magnetic resonance contrast agent. *Magma* 2001;12(2-3):128-134.
  168. Roberts TP. Physiologic measurements by contrast-enhanced MR imaging: expectations and limitations. *J Magn Reson Imaging* 1997;7(1):82-90.
  169. Brasch R, Turetschek K. MRI characterization of tumors and grading angiogenesis using macromolecular contrast media: status report. *Eur J Radiol* 2000;34(3):148-155.
  170. Verhoye M, van der Sanden BP, Rijken PF, Peters HP, Van der Kogel AJ, Pee G, et al. Assessment of the neovascular permeability in glioma xenografts by dynamic T(1) MRI with Gadomer-17. *Magn Reson Med* 2002;47(2):305-313.
  171. Crich SG, Biancone L, Cantaluppi V, Duo D, Esposito G, Russo S, et al. Improved route for the visualization of stem cells labeled with a Gd-/Eu-chelate as dual (MRI and fluorescence) agent. *Magn Reson Med* 2004;51(5):938-944.
  172. Papadopoulos MC, Saadoun S, Davies DC, Bell BA. Emerging molecular mechanisms of brain tumour oedema. *Br J Neurosurg* 2001;15(2):101-108.
  173. Jain RK. Transvascular and interstitial transport in tumors. *Adv Exp Med Biol* 1988;242:215-220.
  174. Jain RK. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. *J Natl Cancer Inst* 1989;81(8):570-576.
  175. Tresley RM, Stone LA, Fields N, Maloni H, McFarland H, Frank JA. Clinical safety of serial monthly administrations of gadopentetate dimeglumine in patients with multiple sclerosis: implications for natural history and early-phase treatment trials. *Neurology* 1997;48(4):832-835.

- 
176. Dore-Duffy P, Katychhev A, Wang X, Van Buren E. CNS microvascular pericytes exhibit multipotential stem cell activity. *J Cereb Blood Flow Metab* 2006;26(5):613-624.
  177. Yip S, Sabetrasekh R, Sidman RL, Snyder EY. Neural stem cells as novel cancer therapeutic vehicles. *Eur J Cancer* 2006;42(9):1298-1308.
  178. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. *Nature* 2001;414(6859):105-111.
  179. Bjerkvig R, Tysnes BB, Aboody KS, Najbauer J, Terzis AJ. Opinion: the origin of the cancer stem cell: current controversies and new insights. *Nat Rev Cancer* 2005;5(11):899-904.